

SUBJECT INDEX

- + 1 inj of glulisine 927-P
 1 hour plasma glucose 728-P
 1, 5 anhydroglucitol 1209-P, 1586-P
 11 β -HSD-1 1878-P
 12 hydroxyeicosatetraenoic acid 1762-P
 12 lipoxygenase 1762-P
 14-3-3 ζ 1960-P
 2 oleoyl glycerol 1119-P
 2 year follow-up 976-P
 25 hydroxyvitamin D 499-P, 1539-P
 3 hydroxybutyrate 1059-P
 3 TPI therapy 2366-PO
 A1c 32-OR, 259-OR, 683-P, 1176-P, 1223-P, 1367-P, 1383-P, 2222-PO
 A1chieve 902-P
 A2-adrenoceptor 585-P
 A2A adenosine receptor 2097-P
 ABCC10 1604-P
 ABCC8 gene 2426-PO
 ABCG1 cholesterol transporter 506-P
 Abdominal visceral fat 60-OR, 2088-P, 2648-PO
 Abdominal obesity 1477-P, 1481-P, 1513-P, 1994-P, 1994-P, 2080-P, 2658-PO
 ABPM 470-P
 Acanthosis Nigricans 2636-PO
 Acarbose 1040-P, 2077-P, 2401-PO, 2416-PO
 Accelerometer 1520-P
 Acceptance of insulin therapy 690-P
 Access to care 2481-PO
 ACCORD trial 166-OR
 Acculturation 2520-PO
 Accuracy 2349-PO
 ACE2/ang-(1-7)/Mas 2123-P
 Acetylation 625-P
 Acetyl-coa carboxylase 1868-P
 Acid labile subunit 1914-P
 Acidic FGF 520-P
 Acot7 2171-P
 Actin remodeling 1668-P
 Actin 1737-P
 Acute therapy 1139-P
 Acyl-coa thioesterase 1816-P
 Adaptable dosing 919-P
 Adaptive optics scanning laser ophthalmoscopy 353-OR
 Adaptive thermogenesis 87-OR
 ADA's ABC goals 450-P
 Add on therapy 1039-P, 1524-P
 Add on to metformin 266-OR, 1074-P, 1077-P
 Add on to pioglitazone 1055-P
 Addiction 818-P, 1757-P
 Adenosine A1 receptors 2205-P
 Adenosine A2a agonism 1948-P
 Adenosine 2097-P
 Adherence 685-P, 759-P, 801-P, 815-P, 982-P, 1228-P, 1429-P, 1528-P, 2379-PO
 Adipocyte cell death 632-P
 Adipocyte differentiation 1679-P, 1967-P
 Adipocyte fatty acid-binding protein 1490-P
 Adipocyte function 2012-P
 Adipocyte MHCII 182-OR
 Adipocyte 185-OR, 273-OR, 1666-P, 1668-P, 1671-P, 1672-P, 1673-P, 1676-P, 1681-P, 1961-P, 2587-PO, 2595-PO
 Adipocytokine 473-P, 2624-PO
 Adipose tissue metabolism 2581-PO
 Adipogenesis 1663-P, 1668-P, 1954-P, 1998-P, 1998-P, 2087-P, 2633-PO
 Adipokine 316-OR, 603-P, 1214-P, 1267-P, 1267-P, 1306-P, 1338-P, 1881-P
 Adiponectin 312-OR, 748-P, 1112-P, 1265-P, 1291-P, 1490-P, 1600-P, 1727-P, 1750-P, 2005-P, 2040-P
 Adipor 1112-P
 Adipose derived stem cell (ADSC) sheets 635-P
 Adipose inflammation 182-OR, 225-OR, 1934-P, 1934-P, 2577-PO
 Adipose tissue ER stress 2026-P
 Adipose tissue fibrosis 90-OR
 Adipose tissue inflammation 188-OR, 1935-P, 1935-P
 Adipose tissue iron 1963-P
 Adipose tissue macrophage 1664-P, 1932-P
 Adipose tissue mechanical properties 1981-P
 Adipose tissue 159-OR, 184-OR, 281-OR, 286-OR, 1199-P, 1397-P, 1670-P, 1675-P, 1678-P, 1700-P, 1984-P, 2006-P, 2035-P, 2239-PO
 Adipose triglyceride lipase 2151-P
 Adiposity indices 1993-P
 Adiposity 1220-P, 1340-P, 1347-P
 Administrative data 1533-P
 Adolescence 813-P, 1216-P, 1244-P, 1255-P, 1259-P, 1260-P, 2472-PO
 Adolescence obesity 1206-P
 Adolescent females 769-P
 Adoleseents 172-OR, 674-P, 674-P, 771-P, 801-P, 808-P, 869-P, 1225-P, 1250-P, 1252-P
 Adrenomedullin 536-P
 Adult pancreatic duct cells 2130-P
 Adults 2544-PO
 Advanced glycosylated end products 1249-P, 1432-P, 1718-P, 2290-PO
 Adverse drug effects 154-OR
 Adverse reactions to statins 613-P
 Adverse risks 1421-P
 Advocate 684-P
 Aeging 1326-P
 Aerobic capacity 224-OR
 Aerobic exercise 227-OR, 728-P, 735-P
 African American 737-P, 823-P, 825-P, 1390-P, 1802-P, 2059-P
 Africans 620-P, 747-P, 1383-P, 2061-P
 Age at menopause 1576-P
 Age at onset 558-P, 1555-P
 Age inhibitor 1143-P
 Age 565-P, 2043-P
 Aggressiveness 232-OR
 Aging 333-OR, 337-OR, 568-P, 1059-P, 1321-P, 1588-P, 1620-P, 1711-P, 1947-P, 2486-PO, 2621-PO
 Agonist 2419-PO
 Agrp 1902-P
 AHA guidelines 17-OR, 438-P
 AHA 2434-PO
 AICAR 2593-PO
 Aiko 510-P
 Akita 2185-P
 Akt 1696-P, 1809-P
 Akt1 1729-P
 Akt2 1681-P
 Ala 2628-PO
 Albiglutide 329-OR, 959-P, 960-P, 961-P, 963-P, 994-P, 1002-P, 1003-P, 1004-P, 1339-P, 1640-P, 2389-PO
 Albumin creatinine ratio 544-P
 Albuminuria 527-P, 541-P, 551-P, 552-P, 554-P, 556-P, 863-P, 945-P, 1061-P, 1140-P, 2228-PO, 2232-PO, 2265-PO, 2512-PO
 Alcohol 1225-P
 Alcohol consumption 2302-PO
 Aleglitazar 1115-P, 1118-P
 Algorithm 732-P, 840-P
 All cause mortality 22-OR, 396-P, 1599-P
 All trans retinoic acid 1669-P
 Alogliptin 1023-P, 1043-P, 2134-P, 2423-PO
 Alpha 1 microglobulin 2265-PO
 Alpha cell 386-OR, 1698-P, 1891-P, 2127-P, 2687-PO
 Alpha hydroxybutyrate 1381-P
 Alpha klotho 556-P
 Alpha-to-beta cell reprogramming 199-OR
 Alstrom syndrome 2557-PO
 Alzheimer's disease 1428-P, 1895-P, 2284-PO
 Ambulance service 249-OR
 Ambulatory blood pressure 426-P, 470-P, 1033-P
 American Indian healing concepts 682-P
 American Indians 11-OR, 665-P, 2533-PO
 Amino acid metabolites 1826-P
 Amino acid sensing 1956-P
 Amino acids 1760-P, 1775-P, 1832-P
 AMPK 446-P, 490-P, 715-P, 1710-P, 1711-P, 1795-P, 1807-P, 1847-P, 1857-P, 1864-P, 1871-P, 2197-P
 Amputation 221-OR
 Amylin 110-OR, 2429-PO
 Amylinomimetics 1016-P, 1019-P
 Amyloid 2113-P
 Anaerobic threshold 2318-PO
 Anagliptin 210-OR
 Analgesic 562-P, 1128-P, 1146-P
 Analog-insulin 2353-PO
 Angiogenesis impairment 313-OR
 Angiogenesis 227-OR, 350-OR, 414-P, 1726-P, 2035-P
 Angiopoietin-like 4 1928-P
 Angiosome model 415-P
 Angiotensin II 507-P, 1853-P, 2205-P
 Angiotensin-(1-7) 1702-P
 Angiotensin-converting enzyme 2 1702-P
 ANGPTL8 1879-P
 Animal 2629-PO
 Animal model 1123-P
 Ankle pressure 2045-P, 2229-PO
 Anterior chamber of the eye 348-OR
 Anthropometry 1387-P, 2635-PO
 Anti-islet antibodies 2548-PO
 Anti platelet drug 418-P
 Anti-thyroid antibodies, anti-gastric antibodies 1575-P
 Antibiotics 1939-P
 Antibodies against pancreatic islet antigens 1575-P
 Antibodies to other autoimmune diseases 1575-P
 Antibodies 25-OR
 Antibody negative diabetes 1358-P, 1391-P
 Anti-CD3 antibody 2391-PO
 Antidiabetic 165-OR
 Antidiabetic drug 2404-PO
 Antidiabetic medication 1480-P, 2510-PO
 Antidiabetic therapy 1421-P, 2392-PO
 Anti-drug antibody 1009-P
 Anti-GAD antibody 2470-PO
 Anti-hyperglycemia 1950-P
 Antihyperglycemic agent 2356-PO
 Anti-hyperglycemic effect 1949-P

- Anti-hypertensive 2431-PO
 Anti-inflammation 1133-P, 2164-P
 Antilipolysis with acipimox 714-P
 Antioxidant 230-OR, 1821-P
 Anti-VEGF agents 355-OR
 Anti-VEGF therapy 591-P, 602-P
 Anti-VEGF 2433-PO
 Anxiety 2515-PO
 Aortic impedance analysis 1143-P
 Aortic stiffness 336-OR
 AP-MS 1736-P
 ApoA5 206-OR
 Apob48 209-OR, 616-P
 Apolipoprotein B 1412-P
 Apolipoprotein J 615-P, 1771-P, 1995-P
 Apoptosis ARC amyloid hiapp 2095-P
 Apoptosis 2-OR, 103-OR, 108-OR, 149-OR, 440-P, 983-P, 1952-P, 2099-P, 2102-P, 2103-P, 2104-P, 2105-P, 2664-PO
 Appetite 1198-P
 Arab pedigrees 2558-PO
 ARB 1526-P
 Archimedes model 395-P
 Arginine 2180-P
 Arrhythmia 147-OR
 Arterial stiffness 425-P, 459-P, 475-P, 2066-P, 2432-PO, 2491-PO
 Artificial pancreas 232-OR, 234-OR, 237-OR, 238-OR, 390-P, 390-P, 937-P, 943-P, 943-P, 949-P, 951-P, 954-P, 1147-P, 2374-PO
 ARX 2121-P
 Aryl hydrocarbon receptor 1684-P
 Asian 1478-P
 Asian American 320-OR, 71-OR, 1305-P
 Asian Indian 1534-P, 1536-P
 Asian patients 1076-P
 Aspartate amino transferase 2275-PO
 ASPIRE in-home 231-OR, 936-P, 940-P, 944-P, 2369-PO
 Assessment-tool 16-OR
 Association 1609-P, 2518-PO
 Asthma 368-OR
 Astrocyte dysfunction 586-P
 Asymmetric dimethylarginine 1780-P
 ATF4 1819-P
 Atf6 2100-P
 Atherogenic dyslipidemia 623-P
 Atherogenic 1207-P
 Atherosclerosis 7-OR, 312-OR, 409-P, 430-P, 435-P, 485-P, 495-P, 498-P, 509-P, 1135-P, 1539-P, 1682-P, 1682-P, 1933-P, 2047-P, 2242-PO, 2623-PO
 Atpmax 1862-P
 Attitude 694-P
 Autoantibodies 557-P, 1582-P, 1652-P, 2564-PO
 Autoantibody 1642-P
 Autoimmune diabetes 180-OR, 1529-P
 Autoimmune regulator 1580-P
 Autoimmunity 179-OR, 1541-P, 1637-P, 1637-P, 1653-P, 2221-PO, 2563-PO
 Automated telephone self management 321-OR
 Automated upload of SMBG result 1159-P
 Autonomic dysfunction 217-OR
 Autonomic neuropathy 573-P, 2274-PO
 Autophagy 51-OR, 313-OR, 1137-P, 1696-P, 1752-P, 1805-P, 1810-P, 1830-P, 1869-P, 2102-P, 2108-P
 Avian 517-P, 2247-PO
 B arrestin2 2098-P
 B cell 47-OR, 105-OR, 309-OR, 1844-P, 2129-P, 2132-P, 2134-P, 2206-P, 2683-PO
 B cell death 106-OR
 B cell dysfunction 2155-P
 B cell expansion 2118-P
 B cell function 835-P, 1018-P, 1445-P, 1534-P, 2074-P, 2152-P, 2286-PO
 B cell neogenesis 200-OR
 B cell dysfunction 2155-P
 B12 deficiency 2505-PO
 B7.1 537-P
 B7-H4 & beta cell stress 27-OR
 B7-H4 as biomarker in T1D 27-OR, 1638-P
 Balanced diet 752-P
 Bapwv 430-P
 Bardet-biedl syndrome 2557-PO
 Bariatric surgery 98-OR, 101-OR, 302-OR, 1828-P, 1941-P, 1941-P, 2000-P, 2005-P, 2005-P, 2006-P, 2006-P, 2013-P, 2013-P, 2020-P, 2040-P, 2054-P, 2057-P, 2070-P, 2072-P, 2081-P, 2085-P, 2276-PO, 2647-PO
 Barriers 688-P, 821-P, 2477-PO
 Barriers to care 680-P
 Barriers to insulin use or insulin therapy 1325-P
 Basal bolus insulin 929-P, 1162-P, 1241-P
 Basal hyperglycemia 883-P
 Basal insulin 254-OR, 331-OR, 473-P, 908-P, 916-PO, 918-P, 920-P, 927-P, 997-P, 2309-PO, 2363-PO
 Basal insulin and oral drugs (BOT) 1546-P
 Basal insulin patch 953-P
 Basal insulin peglispro (BIL, LY2605541) 886-P, 893-P, 897-P, 899-P, 900-P, 913-P
 Basal-bolus therapy 931-P, 1546-P
 BDNF 2529-PO
 Beckwith-wiedemann syndrome 2179-P
 Behavior 807-P
 Behavior change 670-P, 681-P, 780-P
 Behavioral lifestyle intervention 9-OR, 1250-P
 Behavioral mental health 764-P
 Beige 1972-P
 Beige fat cells 87-OR
 Benign paroxysmal positional vertigo 1437-P
 Berberine (BBR) 2007-P
 Beta adrenergic signaling 1970-P
 Beta cell 108-OR, 276-OR, 305-OR, 347-OR, 2108-P, 2113-P, 2113-P, 2166-P, 2188-P, 1658-P, 1728-P, 1735-P, 1746-P, 2115-P, 2117-P, 2127-P, 2133-P, 2142-P, 2151-P, 2154-P, 2162-P, 2163-P, 2175-P, 2193-P
 Beta cell aging 203-OR
 Beta cell apoptosis 104-OR, 2093-P
 Beta cell dysfunction 1205-P, 1466-P, 1473-P
 Beta cell function 83-OR, 107-OR, 120-OR, 193-OR, 194-OR, 195-OR, 327-OR, 328-OR, 341-OR, 883-P, 987-P, 1023-P, 1082-P, 1096-P, 1298-P, 1398-P, 1519-P, 1606-P, 1747-P, 1756-P, 2005-P, 2146-P, 2182-P
 Beta cell mass 191-OR, 198-OR, 202-OR, 2132-P, 2135-P
 Beta cell neogenesis 2125-P
 Beta cell preservation 174-OR
 Beta cell proliferation 42-OR, 197-OR, 201-OR, 307-OR, 2111-P, 2111-P, 2139-P, 2186-P, 2202-P
 Beta cell proteome 204-OR
 Beta cell regeneration 341-OR, 2137-P
 Beta cell regulation 1767-P
 Beta cell replication 2110-P
 Beta cell response 2602-PO
 Beta cell stress and damage 1638-P
 Beta cell transcriptome 204-OR
 Beta3 adrenergic receptor 2001-P
 Beta-cell development 2114-P, 2122-P
 Beta-cell failure 43-OR
 Beta-cell loss 306-OR
 Beta-cell maturation 2119-P
 Beta-cell survival 2200-P
 Beta-hydroxybutyrate 92-OR
 Betatrophin 618-P, 1022-P, 1735-P, 1879-P, 2167-P, 2669-PO
 BG-IG time lag 838-P
 Bias 864-P
 Bile acid malabsorption 1097-P
 Bile acid sequestrant 1898-P
 Bile acids 1044-P, 1898-P, 1911-P
 Bile salts 1906-P
 Bilirubin 1519-P
 Bim 106-OR
 Bioavailability 2383-PO
 Biological markers 1368-P
 Biomarkers 169-OR, 606-P, 651-P, 1214-P, 1462-P, 1462-P, 1887-P, 2428-PO, 2559-PO
 Bionic pancreas 237-OR
 Biosensor 841-P, 861-P
 Biphasic glucose-stimulated insulin secretion 2149-P
 Biphasic insulin aspart 30 902-P, 914-P
 Biphenyl derivative 1068-P
 Birth weight 1240-P, 1310-P, 2527-PO
 Bisphenol A 1485-P, 1553-P, 2562-PO
 BK channels 484-P
 Bladder cancer 1109-P, 2281-PO
 Blood glucose control 782-P
 Blood glucose meter 851-P, 875-P, 876-P, 2350-PO
 Blood glucose monitoring 1203-P, 2207-PO, 2345-PO, 2349-PO
 Blood glucose self-monitoring 13-OR
 Blood glucose variability 866-P, 997-P
 Blood glucose 813-P
 Blood pressure 470-P, 850-P, 2418-PO
 Blood volume 2354-PO
 Blood-brain barrier transport 2058-P
 BMI cutpoint 71-OR
 BMI 1248-P, 1305-P, 1571-P
 BMI, physical activity 1354-P
 BMP antagonists 1998-P
 BMP7 246-OR, 1666-P
 BNP 457-P, 1347-P, 1825-P, 2260-PO
 Body adiposity index 2066-P
 Body composition 157-OR, 1248-P, 1276-P, 1276-P, 2028-P, 2055-P, 2061-P, 2652-PO
 Body fat percentage 2329-PO
 Body mass index 459-P, 1234-P, 1295-P, 1340-P, 1511-P, 1543-P, 1574-P
 Body weight 798-P, 2077-P
 Body weight regulation 241-OR
 BOLD fmri 1996-P
 Bolus calculation 16-OR, 2350-PO
 Bolus insulin dosing 2369-PO
 Bone 1127-P, 2514-PO
 Bone health 2485-PO
 Bone marrow 2633-PO, 2643-PO
 Bone marrow microenvironment 596-P
 Bone marrow monocyte 1974-P
 Bone mineral density 1258-P
 Bradykinin 645-P
 Brain 40-OR, 95-OR, 143-OR, 158-OR, 325-OR, 2585-PO
 Brain atrophy 563-P
 Brain imaging 385-OR
 Brain microstructures 1198-P
 Brain MRI 333-OR, 789-P
 Brain neurometabolites 2624-PO
 Branched chain amino acids 1697-P, 1818-P, 1931-P

- Breastfeeding 1300-P, 1469-P, 1470-P, 1471-P
 Brittle diabetes 2366-PO
 Brown adipocyte differentiation 183-OR
 Brown adipose tissue 186-OR, 246-OR, 295-OR, 1199-P, 1926-P, 1946-P, 2001-P, 2031-P, 2043-P
 Brown fat function 181-OR
 BSCL2 2022-P
 Budget impact 1178-P
 C elegans 2583-PO
 C peptide 1445-P, 1541-P
 CABG 5-OR
 CADM1 2184-P
 Caesarean delivery 2474-PO
 Caffeic acid 1801-P
 Caffeine 1432-P
 Calcaneotomy 661-P
 Calcitonin 2175-P
 Calcium 1890-P
 Calorie restriction 1620-P
 Canagliflozin 109-OR, 263-OR, 268-OR, 798-P, 1032-P, 1032-P, 1034-P, 1078-P, 1092-P, 1093-P, 1095-P, 1096-P, 1181-P, 1189-P, 1190-P, 1765-P
 Cancer 1421-P, 1649-P, 1740-P, 1759-P, 1892-P, 2565-PO
 Cancer risk 1392-P, 1440-P
 Cannabinoid receptor 2673-PO
 Capillary blood glucose 2347-PO
 Captopril 533-P
 Carbohydrate 946-P
 Carbohydrate counting 943-P
 Carbohydrate diet 1481-P
 Carbohydrate estimation 16-OR
 Carbohydrate oxidation 137-OR
 Carbonyl scavengers 2247-PO
 Cardiac dysfunction 471-P
 Cardiac events 454-P
 Cardiac function 2497-PO
 Cardiac hypertrophy 1957-P
 Cardiac insulin resistance 411-P
 Cardiac mitochondria 483-P
 Cardiac mortality 483-P
 Cardiac prognosis 457-P
 Cardiac remodeling 1135-P
 Cardiac stem cells 2-OR, 1137-P
 Cardiac structure 2497-PO
 Cardiac surgery 1013-P
 Cardio-ankle vascular index 472-P
 Cardio metabolic disease 1482-P
 Cardiometabolic function 1990-P
 Cardio metabolic profile 2025-P
 Cardio metabolic risk 747-P, 1489-P
 Cardiomyocyte 447-P
 Cardioprotection 1149-P
 Cardio protective drugs 2460-PO
 Cardiopulmonary bypass 622-P
 Cardio-renal complications 636-P
 Cardio respiratory fitness 164-OR, 2315-PO
 Cardiothoracic surgery 933-P
 Cardiovascular 432-P, 474-P, 1060-P, 1339-P, 1940-P, 1940-P
 Cardiovascular autonomic dysfunction 569-P
 Cardiovascular autonomic neuropathy 115-OR, 549-P, 566-P, 584-P, 745-P, 2516-PO
 Cardiovascular complications 413-P
 Cardiovascular disease 7-OR, 339-OR, 417-P, 442-P, 444-P, 445-P, 449-P, 1099-P, 1261-P, 1328-P, 1329-P, 1341-P, 1342-P, 1346-P, 1348-P, 1349-P, 1888-P, 2408-PO, 2429-PO, 2485-PO, 2496-PO
 Cardiovascular disorder 2651-PO
 Cardiovascular effects 1899-P
 Cardiovascular event risk 462-P
 Cardiovascular events 419-P, 464-P, 1132-P, 1136-P, 1338-P
 Cardiovascular mortality 469-P
 Cardiovascular outcomes 164-OR
 Cardiovascular risk 465-P, 1350-P, 2063-P, 2080-P, 2228-PO, 2230-PO, 2605-PO, 2641-PO, 2647-PO
 Cardiovascular risk effect 999-P
 Cardiovascular risk factors 0338-OR, 448-P, 626-P, 1237-P, 1257-P, 1351-P, 2234-PO
 Cardiovascular risk in prediabetes 412-P
 Card-sorting 2340-PO
 Care transition 1164-P
 Carnitine 1834-P
 Carnosinol glutathione peroxidase 4 1987-P
 Carotenoid 1965-P
 Carotid intima-media thickness 435-P, 442-P, 1336-P, 1539-P, 1572-P, 1660-P
 Carotid plaque 2236-PO
 Carrageenan 1724-P
 Case control study 1433-P
 Caspase 8 185-OR
 Casting 652-P
 Cataract 604-P
 Cathepsin k 1967-P
 Caveolin-1 1691-P
 CB1R inverse agonist 1082-P
 CCM 564-P
 CCR7 279-OR
 CD137 1632-P
 CD163 529-P, 1923-P
 CD4 T cells 179-OR
 CD44 1934-P
 CD59 2241-PO
 CD71 2124-P
 CDH13 polymorphisms 1600-P
 CDKAL1 153-OR
 CDP138 1986-P
 Cebix 588-P
 Celiac disease 30-OR, 1258-P
 Cell cycle 498-P
 Cell proliferation 983-P
 Cell sorting 2115-P
 Cell transplantation 567-P
 Central insulin resistance 1284-P
 Central nervous system 93-OR, 560-P, 560-P
 Central nutrient sensing 1833-P
 Central obesity 1881-P
 Central retinal artery equivalent 592-P
 Central retinal vein equivalent 592-P
 Cephalic phase responses 1761-P
 Ceramide 1685-P, 1709-P, 1738-P, 1854-P, 1855-P
 Cerebral hemoglobin 2462-PO
 Cerebral infarction 2233-PO
 Cerebral microvasculature 581-P
 Cerebrospinal fluid 1999-P
 Cerebrovascular attack 477-P
 Cerebrovascular disease 426-P
 Change in hba1c 1192-P
 Change in intra abdominal fat 1343-P
 Charcot 652-P
 Chemerin 465-P, 2088-P, 2623-PO
 Chemerin, fetuin- A, CRP, TNF-alpha 2548-PO
 Chemokines 110-OR, 2639-PO
 Chewing 1903-P
 Child 15-OR, 1232-P, 1232-P, 1240-P
 Childhood diet 1557-P
 Childhood obesity 1201-P, 1217-P, 2034-P
 Childhood type 1 diabetes 2465-PO
 Children 28-OR, 29-OR, 159-OR, 167-OR, 571-P, 855-P, 1199-P, 1204-P, 1210-P, 1251-P, 1644-P, 2540-PO
 China 1475-P
 Chinese 2376-PO
 Chip-seq 1590-P
 Cholesterol 214-OR, 2108-P
 Cholesterol efflux 506-P
 CHOP 36-OR, 1664-P
 Chrebp 42-OR, 514-P, 1677-P, 2186-P, 2203-P
 Chromatin 1680-P
 Chromium in type 2 diabetes 57-OR
 Chromium-insulin 1734-P
 Chronic care model 2443-PO
 Chronic disease improvement 1150-P
 Chronic hepatitis C 2612-PO
 Chronic inflammation 1665-P, 1954-P, 1973-P, 2015-P
 Chronic kidney disease 52-OR, 535-P, 549-P, 1377-P, 1431-P, 1513-P, 2257-PO, 2266-PO, 2510-PO, 2512-PO
 Chronic pancreatitis 86-OR
 Chronic wounds 1439-P
 Chronotype 2534-PO
 Cigarette smoke 1854-P, 1855-P
 Ciliopathies 2142-P
 Combination 2395-PO
 CIMT 439-P
 CIPII 941-P
 Circadian clock 756-P, 105-OR, 2592-PO
 Circadian control 39-OR
 Circadian rhythm 351-OR, 1874-P, 1894-P, 2534-PO
 Circadian 1912-P, 1927-P
 Circulating mitochondrial DNA 2062-P
 Citric acid cycle 1865-P
 CKD-EPI 550-P
 Claim database 2402-PO
 Clinical care targets to improve glycemic control 803-P
 Clinical care 1499-P
 Clinical characteristics 2507-PO
 Clinical effectiveness 2488-PO
 Clinical inertia 323-OR, 1184-P, 2439-PO
 Clinical practice 1006-P, 1181-P
 Clinical prediction models 1363-P
 Clinical research 2546-PO
 Clinical setting 824-P
 Clinical trial 172-OR, 420-P, 1116-P, 1332-P, 1512-P, 1592-P, 1592-P
 Clinician experience 1182-P
 Clinical guidelines 1455-P
 Clock 1824-P
 Closed loop 233-OR, 235-OR, 236-OR, 774-P, 937-P, 939-P, 942-P, 948-P, 949-P, 952-P, 2367-PO, 2374-PO
 Cluster randomized trial 360-OR
 Clusterin 1995-P
 CNX-013-B2 1084-P
 Coaching program 699-P
 Cocaine 1433-P
 Cocoa 1064-P, 1859-P
 Coding variation 278-OR
 Coeliac disease 2543-PO
 Cognition 334-OR, 789-P, 831-P, 1230-P, 1231-P, 1231-P, 1454-P
 Cognitive behavioral 765-P
 Cognitive decline 581-P
 Cognitive deficit 1979-P
 Cognitive disorders 568-P
 Cognitive dysfunction 337-OR, 2086-P
 Cognitive function 480-P
 Cognitive impairment 1323-P, 2091-P
 Cognitive intervention 757-P
 Cognitive-behavioral therapy 767-P

- Cohort study 1360-P, 1385-P, 1553-P
 Cold 2001-P
 Collagen VI 1981-P
 Collateral vessels 508-P
 College 684-P
 Coltelizumab 2391-PO
 Combination immunotherapy 173-OR
 Combination therapy 1071-P
 Combination 64-OR, 65-OR, 66-OR
 Community 482-P, 698-P, 1186-P
 Community health centers 1185-P
 Community health workers 256-OR, 676-P, 765-P, 1194-P
 Community organization 707-P
 Community-based 708-P
 Community-clinical partnership 665-P
 Comorbidities 1319-P, 1493-P, 1498-P
 Comparative economic impact 1152-P
 Comparative effectiveness research 1413-P, 2408-PO
 Comparative pharmacokinetics and pharmacodynamics 889-P, 890-P
 Comparison studies 687-P
 Compliance 816-P, 994-P, 2333-PO
 Complications 115-OR, 340-OR, 352-OR, 354-OR, 518-P, 588-P, 594-P, 648-P, 656-P, 1236-P, 1427-P, 2243-PO, 2249-PO, 2452-PO, 2463-PO, 2509-PO
 Composite endpoint 2490-PO
 Comprehensive diabetes center 764-P
 Computed tomography coronary angiography 434-P
 Computer insulin management 2444-PO
 Concentrated insulin 2359-PO
 Conditioned medium 2198-P
 Conduit artery function 448-P
 Cones 598-P
 Congenital generalized lipodystrophy 2022-P
 Congenital hyperinsulinism 406-P, 2684-PO
 Contact heat evoked potential stimulation (CHEPS) 114-OR
 Continuous glucose monitoring 63-OR, 80-OR, 102-OR, 235-OR, 398-P, 760-P, 762-P, 785-P, 836-P, 837-P, 838-P, 839-P, 840-P, 843-P, 845-P, 846-P, 847-P, 854-P, 855-P, 856-P, 858-P, 860-P, 862-P, 865-P, 866-P, 867-P, 868-P, 873-P, 879-P, 880-P, 906-P, 938-P, 939-P, 1051-P, 1091-P, 1197-P, 1209-P, 1227-P, 1228-P, 1253-P, 1733-P, 2351-PO, 2352-PO, 2360-PO, 2417-PO
 Contrast enhanced ultrasound (CEU) 1838-P
 Controlled attenuation parameter 2084-P, 2611-PO
 Conversation maps 695-P, 697-P
 COPII dependent ER export 2187-P
 Coping 825-P, 826-P
 Coping with diabetes 257-OR
 Copy number variation 1583-P
 Corneal confocal microscopy 117-OR, 571-P, 573-P, 583-P, 2276-PO, 2282-PO
 Coronary angiography 462-P
 Coronary artery 484-P
 Coronary artery bypass graft surgery 909-P
 Coronary artery calcification 424-P, 458-P, 2547-PO
 Coronary artery disease 8-OR, 433-P, 436-P, 437-P, 451-P, 463-P, 1483-P, 2240-PO, 2547-PO
 Coronary artery stenosis 434-P, 1327-P, 1327-P
 Coronary atherosclerosis 422-P, 423-P, 423-P
 Coronary heart disease 429-P, 458-P, 465-P, 1426-P, 2002-P, 2002-P
 Coronary microcirculation 1144-P
 Coronary multi-detector computed tomography 6-OR
 Corticosterone 1882-P
 Cortisol 1790-P, 1874-P, 1874-P
 Cost 407-P, 1156-P, 1156-P, 1294-P, 2452-PO
 Cost analysis 1167-P
 Cost saving 1183-P
 Cost-effectiveness 17-OR, 19-OR, 23-OR, 640-P, 1153-P, 1176-P, 1179-P, 1195-P, 1299-P, 2435-PO, 2440-PO
 Co-stimulatory molecules 176-OR
 Costs 781-P, 1174-P
 Counterregulation 148-OR
 Counter regulatory responses 250-OR
 Covariates 1379-P
 C-peptide 283-OR, 588-P, 1229-P, 1503-P, 1568-P, 1643-P, 2166-P, 2540-PO
 C-peptide clearance 1765-P
 CPPED1 1590-P
 CPR 2396-PO
 CRDH 1056-P
 Cre recombinase 1618-P
 C-reactive protein 2063-P
 Creative expression 1163-P
 Creb3l3 1782-P
 Critical illness 404-P
 Critical limb ischaemia 415-P
 Crosslaps 1543-P
 CRP 1625-P
 CRT3C 181-OR
 CSF 40-OR
 CSII 133-OR, 938-P, 947-P, 950-P, 2356-PO
 CTLA4-Ig 537-P
 Cultural health beliefs 763-P
 Curcumin 1072-P, 2162-P
 CVD risk factors 449-P, 1477-P
 CVD risk reduction 669-P
 CVD 381-OR
 CXCL10 1636-P, 1997-P
 Cyclin D2 2111-P
 CYP2C9 1069-P
 Cystatin C 577-P
 Cystic fibrosis related diabetes 1908-P, 2107-P
 Cytokine 1232-P, 1568-P, 1582-P, 1839-P, 2093-P, 2199-P
 Cytokine-induced apoptosis 2567-PO
 Cytoskeleton 108-OR
 Cytotoxic T cell 1647-P
 DAD 874-P
 DAG 35-OR
 Dairy 1465-P
 Dammarane-type triterpene 1949-P, 1950-P
 Dapagliflozin 265-OR, 267-OR, 269-OR, 802-P, 1031-P, 1033-P, 1036-P, 1050-P, 1054-P, 1076-P, 1094-P, 1099-P, 2218-PO, 2418-PO
 DASH diet 460-P
 Database 2541-PO
 Dawn phenomenon 938-P, 1790-P
 Db/db mice 585-P
 DCCT/EDIC study 478-P
 De novo lipogenesis 1776-P, 1786-P
 Decision support 1151-P
 Decision-support electronic health records 1155-P
 Dedifferentiation 2113-P, 2117-P, 2141-P
 Dedifferentiation apoptosis 310-OR
 Degludec 903-P, 904-P, 905-P
 Dementia 1435-P
 DEND Syndrome 2426-PO
 Dental pulp stem cell 574-P
 Depression 255-OR, 261-OR, 647-P, 767-P, 770-P, 771-P, 776-P, 778-P, 787-P, 822-P, 1252-P, 1498-P, 1556-P, 2334-PO, 2407-PO, 2515-PO
 Depression and patient health questionnaire, PHQ2 2539-PO
 Depression prevention 808-P
 Depressive disorder 704-P
 Depressive mood 814-P
 Depressive symptoms 384-OR
 DEPTOR 1779-P
 Desnutrin 2160-P
 Determinants of hypoglycemia 394-P
 Developing countries 1419-P
 Development of hypothalamic circuits 1218-P
 Development 159-OR, 1984-P, 2133-P
 Device 2373-PO, 2387-PO
 Dexamethasone 907-P
 Dexcom 2352-PO
 Dextran sulfate 104-OR
 DGAT1 inhibitor 2105-P
 DHEA 250-OR
 Diabetes alert dogs 874-P
 Diabetes and cancer 1759-P
 Diabetes and disability retirement 1502-P
 Diabetes and prediabetes awareness 1468-P
 Diabetes care 1047-P, 2523-PO
 Diabetes care improvement model 1155-P
 Diabetes care in nursing facilities 1325-P
 Diabetes champions 1195A-P, 2305-PO
 Diabetes clinic 1193-P
 Diabetes complications 166-OR, 877-P, 1424-P, 1430-P, 1434-P
 Diabetes control 1329-P, 2571-PO
 Diabetes diagnosis 2508-PO
 Diabetes distress 14-OR, 255-OR, 683-P, 820-P, 827-P
 Diabetes distress scale 800-P
 Diabetes duration 301-OR, 885-P, 2540-PO
 Diabetes during the holidays 881-P
 Diabetes education 15-OR, 666-P, 666-P, 673-P, 693-P, 700-P, 705-P, 706-P, 2307-PO
 Diabetes epidemiology 1536-P
 Diabetes FORWARD 1089-P
 Diabetes genetics 1613-P
 Diabetes in pregnancy 2479-PO
 Diabetes incidence 76-OR, 170-OR, 383-OR, 1526-P
 Diabetes knowledge test 800-P
 Diabetes loneliness 792-P
 Diabetes management 682-P, 1289-P, 1505-P, 2337-PO, 2449-PO
 Diabetes medication 1426-P
 Diabetes neuropathy 587-P
 Diabetes offspring 1751-P
 Diabetes onset 1633-P
 Diabetes polyneuropathy 112-OR
 Diabetes prediction 1380-P
 Diabetes prevalence 170-OR, 1536-P
 Diabetes prevention 9-OR, 262-OR, 334-OR, 360-OR, 669-P, 679-P, 682-P, 687-P, 688-P, 790-P, 1122-P, 1297-P, 1377-P, 1488-P, 1520-P, 1525-P, 1540-P, 1591-P, 2059-P, 2342-PO, 2343-PO
 Diabetes professional development 672-P
 Diabetes quality improvement, Diabetes CME 672-P
 Diabetes race 1354-P
 Diabetes recognition program 1449-P
 Diabetes related distress 770-P
 Diabetes remission 101-OR
 Diabetes risk factors 2538-PO
 Diabetes risk perception 1297-P
 Diabetes risk 8-OR, 1385-P, 1407-P, 1415-P, 1417-P
 Diabetes screening 1183-P, 1413-P
 Diabetes self-management 321-OR, 665-P, 676-P, 1175-P

- Diabetes status 1336-P
 Diabetes surveillance 1532-P
 Diabetes symptoms 762-P
 Diabetes system improvement 672-P
 Diabetes therapy 373-OR
 Diabetes treatment 151-OR, 2490-PO
 Diabetes-related autoantibodies 1560-P
 Diabetes-related distress 767-P, 787-P, 822-P
 Diabetes-related treatment goals 1093-P
 Diabetes-susceptible gene 1379-P, 1380-P
 Diabetic bladder dysfunction 589-P
 Diabetic cardiomyopathy 4-OR, 461-P, 503-P
 Diabetic complications 3-OR, 560-P, 958-P, 1422-P, 1422-P, 1455-P
 Diabetic dyslipidemia 205-OR, 613-P, 613-P
 Diabetic foot complications 219-OR
 Diabetic foot infection 639-P, 661-P
 Diabetic foot limb salvage 219-OR
 Diabetic foot ulcer 220-OR, 222-OR, 634-P, 640-P, 650-P, 654-P, 660-P, 2292-PO
 Diabetic foot 652-P, 653-P, 663-P, 664-P, 2283-PO, 2291-PO, 2430-PO, 2499-PO
 Diabetic ketoacidosis 454-P, 1187-P, 1230-P, 1239-P, 2451-PO
 Diabetic kidney disease 551-P, 2250-PO
 Diabetic macular edema 349-OR, 355-OR, 591-P, 591-P, 602-P, 2433-PO
 Diabetic miniswine 604-P
 Diabetic mouse bioassay 2572-PO
 Diabetic nephropathy 49-OR, 52-OR, 140-OR, 514-P, 514-P, 515-P, 518-P, 519-P, 520-P, 524-P, 525-P, 526-P, 528-P, 530-P, 532-P, 534-P, 535-P, 537-P, 537-P, 540-P, 547-P, 556-P, 557-P, 562-P, 1128-P, 1146-P, 1429-P, 2248-PO, 2261-PO
 Diabetic neuropathy 79-OR, 111-OR, 114-OR, 117-OR, 563-P, 563-P, 565-P, 565-P, 571-P, 575-P, 578-P, 663-P, 1423-P, 2269-PO, 2273-PO, 2275-PO
 Diabetic older adults 742-P
 Diabetic peripheral neuropathy 572-P, 579-P, 725-P, 2280-PO
 Diabetic polyneuropathy 116-OR, 567-P, 567-P
 Diabetic pregnancy 215-OR, 1272-P
 Diabetic pulmonary complications 53-OR
 Diabetic retinopathy 352-OR, 353-OR, 355-OR, 356-OR, 595-P, 595-P, 605-P, 606-P, 608-P, 609-P, 610-P, 611-P, 1368-P, 1441-P, 1598-P, 2559-PO
 Diabetic screening, diabetic outcomes 1436-P
 Diabetic ulcer 635-P, 1142-P
 Diabetic vasculature 1701-P
 Diabetologist led service 653-P
 Diacylglycerol 1768-P
 Diagnosis 1187-P, 1362-P, 1371-P, 1384-P, 1503-P, 2501-PO, 2502-PO
 Diagnostic criteria-diabetes 1964-P
 Diagnostic 2428-PO
 Dialysis 876-P
 Diaport 941-P
 Diastolic dysfunction 2068-P
 Diazoxide 406-P
 Diet acceptability 753-P
 Diet during pregnancy 1280-P
 Diet induced obesity 1947-P
 Diet intervention 2278-PO
 Diet patterns 1314-P
 Diet quality 74-OR, 737-P, 742-P, 742-P
 Diet 61-OR, 829-P, 2327-PO
 Diet, pregnancy, carbohydrate, fat-free mass 1276-P
 Dietary factors 2518-PO
 Dietary fatty acid metabolism 297-OR
 Dietary fiber 739-P, 750-P, 1937-P, 1937-P
 Dietary fructose 1777-P
 Dietary intake 382-OR, 1475-P
 Dietary lipid 748-P
 Dietary patterns 1472-P
 Dietary polyphenols 58-OR
 Dietary therapy 740-P
 Diet-induced obesity 1983-P, 2602-PO
 Differentiation 187-OR, 347-OR, 1088-P, 2137-P
 Dipeptidyl peptidase inhibitor 422-P
 Dipeptidyl peptidase-4 inhibitor 2-OR, 150-OR, 511-P, 516-P, 1105-P, 1863-P
 DIPSI 1410-P
 Disability 1318-P
 Discontinuation 1521-P, 1522-P
 Discontinuation of statins 613-P
 Disease management 2298-PO
 Disordered eating 773-P, 1246-P
 Disparities 320-OR, 812-P, 1602-P, 2509-PO
 Disposition index 193-OR, 1756-P
 Distal sensory motor polyneuropathy 2523-PO
 DJBL 1104-P, 1906-P
 DKA at diabetes onset 1565-P
 DKA in children 1565-P
 DKA 2469-PO
 DNA damage 2199-P
 DNA methylation 1588-P, 1806-P, 1916-P, 1983-P, 2010-P
 Docosahexanoic acid 1815-P
 Dopamine 712-P, 1824-P, 2020-P
 Dose-finding study 1083-P
 Dose-response 989-P, 1328-P
 Dosing 912-P
 Double diabetes 1541-P
 Douleur neuropathique 4 questions 2275-PO
 Down-titration 1522-P
 DPP-4 inhibitor 152-OR, 153-OR, 210-OR, 545-P, 1024-P, 1027-P, 1048-P, 1083-P, 1098-P, 1100-P, 1133-P, 1135-P, 1840-P, 1840-P, 2400-PO, 2403-PO, 2406-PO, 2417-PO, 2422-PO, 2423-PO
 DPP-4 316-OR, 603-P, 1039-P, 1061-P, 1547-P, 1676-P, 1750-P, 2413-PO
 Driving 260-OR, 696-P
 Drosophila 2601-PO
 Drug naive 959-P
 Drug screening 308-OR
 Drug-drug interaction 570-P, 1080-P
 Drugs use 1440-P
 Dsba-L 2589-PO
 Dual system use 1439-P
 Dulaglutide 330-OR, 962-P, 979-P, 980-P, 2393-PO
 Duodenum 1942-P
 Duration of action 891-P
 Dynamic electrochemistry 875-P
 Dysglycemia 614-P, 1751-P
 Dyslipidemia 206-OR, 208-OR, 619-P, 1814-P, 2532-PO
 Dyspnea 1448-P
 Early childhood 1215-P
 Early diagnosis 2508-PO
 Early discontinuation 898-P
 Early intensive treatment 884-P
 Early response 998-P
 Early screening 358-OR
 Eating behavior 746-P, 967-P, 969-P, 2076-P, 2396-PO
 Eating disorders 773-P
 Echocardiography 1056-P
 Economic analysis 1183-P
 Ectopic fat accumulation 2019-P
 Ectopic fat 2037-P
 Ectopic lipid 195-OR, 206-OR, 244-OR
 EDITION 67-OR, 919-P
 Education 31-OR, 680-P, 684-P, 685-P, 691-P, 695-P, 696-P, 697-P, 766-P, 867-P, 2303-PO, 2304-PO, 2310-PO, 2312-PO
 EEG 253-OR
 Effectiveness 999-P
 Efficacy 996-P
 EGFR 2099-P
 Elderly 1008-P, 1057-P, 1063-P, 1318-P, 1318-P, 1319-P, 1323-P, 1324-P, 1325-P, 1349-P, 2257-PO, 2488-PO, 2632-PO
 Elective surgical patients 1011-P
 Electronic decision support 2375-PO
 Electronic diary 897-P, 913-P
 Electronic health records 764-P
 Electronic medical records 2250-PO
 Electrophysiology 1218-P
 Elimination 899-P
 Embryo metabolism 216-OR
 Embryogenesis 2123-P
 Emergency 407-P
 Emergency department 23-OR
 Emerging adulthood 1169-P
 Emotional distress 768-P
 Emotional processing 815-P
 Empagliflozin 264-OR, 266-OR, 270-OR, 543-P, 1030-P, 1055-P, 1056-P, 1074-P, 1077-P, 1079-P, 1125-P
 Empowerment 675-P
 End stage renal disease 536-P, 924-P, 1453-P
 Endobarrier 879-P, 1104-P, 1906-P
 Endocannabinoid 522-P, 1121-P, 1654-P, 1905-P, 2688-PO
 Endocrine disruptors 1485-P
 Endogenous glucose production 1796-P
 Endoglin 2216-PO
 Endoplasmic reticulum stress 43-OR, 197-OR, 287-OR, 308-OR, 1138-P, 1780-P, 2109-P
 Endothelial cells 38-OR, 401-P, 446-P, 495-P, 1123-P, 1123-P, 1840-P, 2131-P, 2244-PO
 Endothelial dysfunction 316-OR, 481-P, 492-P, 603-P, 1100-P, 2216-PO
 Endothelial function 443-P, 473-P, 497-P, 750-P, 905-P, 1126-P, 1141-P
 Endothelial insulin-resistance 1718-P
 Endothelial repair 494-P
 Endothelial-to-mesenchymal transition 599-P
 Endothelin-1 1842-P
 Endothelium 293-OR, 372-OR, 557-P, 1690-P, 1726-P
 Endothelium-dependent vasodilator response 496-P
 Endotoxemia 404-P, 752-P
 Endotoxin 299-OR
 End-stage renal disease 1425-P
 Endurance exercise 714-P
 Energy balance 1897-P, 2028-P
 Energy expenditure 298-OR, 1966-P, 1991-P
 Energy homeostasis 1218-P
 Energy metabolism 1847-P
 Enhancer 1680-P
 Enos-deficient mice 2125-P
 Enteral nutrition 2519-PO
 Enteroendocrine cells 1117-P, 1880-P, 1922-P
 Enteroendocrine hormones 1898-P
 Enterovirus 178-OR
 Environment and T2D 1826-P
 Environmental factors 168-OR
 Environmental risk factors 1650-P
 Environmental toxicants 1485-P
 Enzyme kinetics 1048-P

- Eolorectal submucosal region 2019-P
 Eosinophils 1772-P
 Epac 2150-P
 Epicardial adipose tissue 2623-PO
 Epicardial fat 463-P
 Epicatechin 1064-P, 1859-P
 Epidemiology ethnicity coronary heart disease race 1333-P
 Epidemiology ethnicity race heart failure 2494-PO
 Epidemiology 77-OR, 922-P, 1329-P, 1347-P, 1351-P, 1386-P, 1391-P, 1420-P, 1434-P, 1441-P, 1459-P, 1465-P, 1512-P, 1513-P, 1529-P, 1553-P, 1554-P, 1559-P, 1573-P, 1592-P, 2516-PO, 2523-PO, 2545-PO, 2546-PO, 2549-PO
 Epigenetics 213-OR, 1588-P, 1806-P, 1826-P, 1826-P, 2010-P, 2553-PO, 2581-PO
 Epigenomics 2552-PO
 Epithelial to mesenchymal transition 347-OR
 Epitopes 1652-P
 Epro 878-P, 897-P, 913-P
 ER stress 36-OR, 105-OR, 309-OR, 1801-P, 1820-P, 1843-P, 1930-P, 2100-P, 2148-P, 2148-P, 2172-P, 2174-P, 2187-P
 Erectile dysfunction 2253-PO, 2277-PO
 ERK 1/2 716-P, 2202-P
 Errors in insulin administration 668-P
 Erythropoietin 1699-P
 ESRD 548-P
 Estimated GFR 550-P
 Estimated glomerular filtration rate 539-P, 2250-PO
 Estradiol 83-OR, 1279-P, 1279-P, 1569-P
 Estrogen receptor alpha 1983-P
 Ethiopians 1399-P
 Ethnic disparities 412-P
 Ethnic/racial minority 803-P
 Ethnicity 600-P, 1382-P, 1427-P, 1764-P, 1802-P, 2045-P, 2056-P, 2229-PO
 Euglycemia 1926-P
 Euglycemic hyperinsulinemic clamp 1357-P, 1731-P
 Euglycemic insulin clamp 448-P
 Europe 2410-PO
 Euthyroidism 60-OR
 Everyday life 681-P
 EWS 1666-P
 Excessive gestational weight gain 1265-P
 Exenatide once-weekly 1192-P
 Exenatide 389-P, 964-P, 968-P, 970-P, 997-P, 998-P, 1013-P, 1022-P, 1022-P
 Exendin 2163-P
 Exercise capacity 1863-P
 Exercise physiology 726-P
 Exercise testing 2318-PO
 Exercise training 710-P, 1113-P
 Exercise 223-OR, 225-OR, 226-OR, 228-OR, 229-OR, 572-P, 711-P, 713-P, 715-P, 716-P, 721-P, 724-P, 725-P, 729-P, 734-P, 829-P, 1161-P, 1219-P, 1807-P, 1852-P, 1856-P, 1864-P, 1949-P, 2314-PO, 2317-PO
 Exercisephysiology 1905-P
 Exocytosis 2144-P
 Exome array 272-OR
 Exome chip 139-OR
 Exome sequencing 139-OR, 140-OR, 633-P, 1579-P, 1601-P
 Exome variants 138-OR
 Experience 2304-PO
 Experimental diabetes 2241-PO
 Experimental mouse models 1650-P
 Explanatory model 2339-PO
 Exposure 892-P
 Expression 1922-P
 Extracellular matrix 33-OR, 1671-P, 1836-P, 2643-PO
 Extramucocellular lipid 1866-P
 Extreme duration type 1 diabetes 2485-PO
 Extreme insulin resistance 1896-P
 Ezetimibe 1924-P
 Falls 1442-P
 Familial diabetes 136-OR
 Familial early-onset type 2 diabetes mellitus 1619-P
 Family history 1496-P, 1507-P
 Family planning vigilance 775-P
 Family 771-P
 Fasting glucose 272-OR, 1992-P
 Fasting plasma glucose 1295-P, 1375-P, 1395-P, 2508-PO
 Fasting 1531-P, 2053-P, 2224-PO
 Fat browning 1674-P
 Fat distribution 1971-P
 Fat fed dog 1674-P
 Fat feeding 43-OR
 Fat mass 1276-P, 1805-P
 Fat oxidation 245-OR
 Fat 243-OR, 1984-P, 2047-P
 Fatigue 721-P, 761-P, 761-P, 793-P
 Fat-induced beta-cell dysfunction 2145-P
 Fatty acid metabolism 1816-P
 Fatty acid oxidation 1827-P
 Fatty acid receptor 2158-P
 Fatty acid saturation 1464-P
 Fatty acid 208-OR, 1465-P, 1465-P
 Fatty acid-dependent beta-cell apoptosis 109-OR
 Fatty acids 378-OR, 1942-P, 2153-P, 2171-P
 Fatty liver 289-OR, 631-P, 1263-P, 1721-P, 1798-P, 1800-P, 1802-P, 1804-P, 1807-P, 1820-P, 2036-P, 2228-PO
 FBS vs. hba1c for diabetes diagnosis Vietnam 1366-P
 Fear of hypoglycemia 785-P, 810-P, 814-P, 832-P, 2213-PO, 2528-PO
 Feasibility study 2341-PO
 Female 1223-P
 Fenofibrate 2249-PO
 Fetal adiposity 2034-P
 Fetal growth 1272-P
 Fetal insulin 212-OR
 Fetal metabolic programming 1916-P
 Fetal programming 717-P, 1263-P, 1280-P
 Fetuin-A 367-OR, 432-P, 2064-P, 2599-PO
 Fetus 1760-P, 1775-P
 FFA 91-OR, 300-OR, 1904-P
 FGF2 215-OR, 2200-P
 FGF21 94-OR, 126-OR, 226-OR, 436-P, 1720-P, 1782-P, 1794-P, 1887-P, 2201-P, 2636-PO
 FGFR 2200-P
 Fiber 755-P
 Fibrinogen 609-P, 1928-P
 Fibroblast growth factor 19 437-P
 Fibroblast growth factor 21 461-P, 1132-P
 Fibrosis 311-OR, 531-P
 FIELD 1132-P
 Fine-mapping 274-OR
 First antidiabetic medication 2402-PO
 First nations 1163-P
 First-degree relatives of patients with T1D 2548-PO
 FIT2 2012-P
 Fixed dose combination 2406-PO
 Fixed-ratio combination 332-OR
 Flaxseed oil 2628-PO
 Flexible diet 675-P
 Flow mediated dilation 492-P
 Fluorescence 1422-P
 Flux analysis 1820-P
 Foam cell 409-P
 Follow-up study 1195-P
 Food insecurity 692-P, 1492-P, 1542-P
 Food intake 380-OR, 1111-P, 1829-P, 1943-P, 1991-P
 Foot care 663-P
 Foot complications 641-P
 Foot ulcer 637-P, 642-P, 647-P, 649-P, 656-P
 Foot ulceration 648-P, 658-P
 Foot 217-OR
 Footwear 660-P
 Formula diet 1480-P
 Foxa2 44-OR
 FOXO1 305-OR, 1721-P, 1809-P, 1814-P
 Foxo6 290-OR
 Fractures 165-OR, 601-P, 1029-P, 1320-P, 1442-P, 1458-P
 Frailty 1321-P, 1326-P
 Framingham score 1332-P
 Free fatty acids 727-P, 736-P, 1114-P, 1829-P, 2161-P, 2669-PO
 Fructosamine 400-P, 1209-P
 Fructose 1557-P, 1786-P, 1999-P, 1999-P
 FTO 1211-P, 1354-P
 Function 1454-P
 Functional connectivity 251-OR
 Functional genomics 275-OR
 Functional MRI 789-P, 2076-P
 Fyn kinase 1651-P, 1679-P, 1871-P
 G protein-coupled receptor 119 1119-P
 GOS2 1811-P
 G6PC2 272-OR, 2147-P
 G6PD 521-P
 GABA 1927-P
 GAD65 autoantibody epitope 28-OR
 Gait alterations 658-P
 Galanin 1708-P
 Gastric bypass 102-OR, 194-OR, 356-OR, 1745-P, 1745-P, 1747-P, 1747-P, 1940-P, 1940-P, 2049-P, 2082-P
 Gastric emptying 1000-P, 1764-P
 Gastric inhibitory polypeptide 1888-P
 Gastric plication 1923-P
 Gastrin 200-OR
 Gastrointestinal hormones 749-P
 Gastrointestinal peptides 1975-P
 Gastrointestinal symptom 1445-P
 Gastrointestinal
 Gastrointestinal-mediated glucose disposal 1877-P
 Gastrojejunostomy 2054-P
 GCK 137-OR, 1418-P
 GCSF 1643-P
 GDM 362-OR, 363-OR, 1291-P, 1303-P, 1304-P
 GDR 1731-P
 Gender differences 1564-P
 Gender disparities 2459-PO
 Gender 62-OR, 297-OR, 1106-P, 1124-P, 1492-P, 2076-P, 2083-P, 2486-PO
 Gene expression 561-P, 1585-P, 1963-P, 2258-PO, 2581-PO
 Gene x environment interaction 1593-P, 1758-P
 Gene x gene interaction 1758-P
 Gene 1628-P
 Generalized anxiety questionnaire, GAD2 2539-PO
 Genetic association 54-OR, 382-OR
 Genetic disorder 93-OR
 Genetic polymorphism 547-P, 2551-PO
 Genetic prediction 1629-P
 Genetic risk 271-OR, 799-P, 1396-P, 1595-P, 1599-P, 1629-P

- Genetic testing 777-P, 1418-P
 Genetic variance 1066-P
 Genetics of dyslipidemia 633-P
 Genetics 26-OR, 138-OR, 276-OR, 364-OR, 559-P, 1358-P, 1358-P, 1369-P, 1578-P, 1594-P, 1601-P, 1606-P, 1607-P, 1608-P, 1625-P, 1626-P, 1777-P, 2034-P, 2558-PO, 2560-PO
 Genome engineering 2674-PO
 Genome interpretation 273-OR
 Genome sequencing 1585-P
 Genome wide association 3-OR, 274-OR, 277-OR
 Genomics 2552-PO
 Gensini score 437-P
 Geospatial analysis of diabetes complication risk 1157-P
 Geriatric diabetes 132-OR
 Geriatric patients 1320-P
 Geriatric scales 2486-PO
 Germany 2545-PO
 Gestational diabetes 75-OR, 213-OR, 324-OR, 357-OR, 359-OR, 360-OR, 361-OR, 364-OR, 670-P, 709-P, 784-P, 1166-P, 1266-P, 1267-P, 1274-P, 1277-P, 1278-P, 1283-P, 1284-P, 1287-P, 1288-P, 1290-P, 1295-P, 1297-P, 1298-P, 1299-P, 1301-P, 1305-P, 1306-P, 1307-P, 1308-P, 1312-P, 1315-P, 1375-P, 1384-P, 1394-P, 1410-P, 1411-P, 1451-P, 1469-P, 1470-P, 1471-P, 1514-P, 2342-PO, 2343-PO, 2474-PO, 2477-PO, 2478-PO, 2483-PO, 2531-PO
 Gestational weight gain 1281-P
 Gestational diabetes mellitus 1273-P
 GFR 1544-P, 1567-P
 GGT 1408-P
 GH 1907-P
 Ghrelin 379-OR, 1211-P, 2625-PO
 GHRL 2261-PO
 Gingival/periodontal inflammation 2525-PO
 Ginkgo biloba 1140-P
 GIP 196-OR, 1590-P, 1904-P, 2658-PO
 Glargine 330-OR, 929-P, 962-P
 Glucalazide 1450-P
 Glimepiride 266-OR, 1450-P, 2226-PO
 Glinides monotherapy 1039-P
 Glipizide 1043-P
 Glis3 198-OR
 Glitazones 1616-P
 Global model 2355-PO
 Global 32-OR
 Glomerular filtration rate 555-P, 1034-P
 GLP 1 agonists 329-OR, 554-P, 994-P, 1789-P
 GLP-1 receptor agonist 456-P, 959-P, 960-P, 961-P, 963-P, 967-P, 976-P, 979-P, 983-P, 1000-P, 1001-P, 1002-P, 1003-P, 1004-P, 1339-P, 1640-P, 1910-P, 2380-PO, 2389-PO
 GLP-1 97-OR, 155-OR, 156-OR, 196-OR, 200-OR, 284-OR, 325-OR, 328-OR, 331-OR, 377-OR, 404-P, 498-P, 711-P, 741-P, 965-P, 984-P, 985-P, 1137-P, 1706-P, 1744-P, 1838-P, 1883-P, 1890-P, 1891-P, 1903-P, 1904-P, 1910-P, 1912-P, 1925-P, 2027-P, 2046-P, 2284-PO, 2398-PO
 GLP-1(32-36) amide 1857-P
 GLP-1R 1736-P, 1909-P, 2163-P, 2182-P
 Glucagon analogue 390-P
 Glucagon antagonist 988-P
 Glucagon effect 1749-P
 Glucagon like peptide 1 1924-P
 Glucagon like peptide 2 205-OR
 Glucagon receptor antagonist 1038-P, 1116-P
 Glucagon receptor knockout mouse 377-OR
 Glucagon secretion 2687-PO, 2688-PO
 Glucagon 234-OR, 236-OR, 237-OR, 238-OR, 248-OR, 365-OR, 937-P, 937-P, 991-P, 1007-P, 1147-P, 1698-P, 1767-P, 1812-P, 1877-P, 1919-P, 2387-PO, 2423-PO, 2684-PO
 Glucagon-like peptide-1 379-OR, 380-OR, 580-P, 993-P, 1011-P, 1020-P, 1021-P, 1119-P, 1192-P, 1764-P, 1888-P, 1899-P, 1913-P, 1915-P, 1918-P, 1946-P, 2379-PO, 2388-PO
 Glucocorticoid effect 1171-P
 Glucocorticoids 1658-P, 1670-P, 1845-P, 1878-P, 1878-P, 1971-P, 2192-P
 Glucokinase activator 122-OR, 1041-P
 Glucokinase 1113-P, 2168-P
 Glucolipotoxicity 1920-P, 2099-P, 2194-P
 Glucometer integration 878-P
 Glucometrics 2345-PO
 Gluconeogenesis 1067-P, 1617-P, 1775-P, 1775-P, 1787-P, 1791-P, 1814-P, 1828-P, 1830-P, 1925-P, 2594-PO
 Glucoregulatory control 862-P
 Glucosamine 116-OR, 216-OR
 Glucose absorption 1049-P
 Glucose clamp 895-P, 896-P, 1715-P, 2226-PO
 Glucose control 1013-P, 2366-PO
 Glucose detection 874-P
 Glucose effectiveness 1777-P
 Glucose excursion 1091-P
 Glucose fluctuation 905-P, 1788-P
 Glucose homeostasis 93-OR, 239-OR, 375-OR, 1705-P, 2497-PO
 Glucose intolerance 1771-P, 1885-P, 2563-PO
 Glucose metabolism 62-OR, 295-OR, 336-OR, 1686-P, 1686-P, 1704-P, 1785-P, 1872-P, 1883-P, 1986-P, 2404-PO, 2461-PO
 Glucose meters 872-P
 Glucose monitoring 844-P, 857-P, 871-P, 2351-PO
 Glucose oxidation 291-OR, 490-P, 490-P
 Glucose production 378-OR, 1942-P, 1942-P
 Glucose progression 1342-P
 Glucose regulation 138-OR
 Glucose self-monitoring 2332-PO
 Glucose sensitivity 191-OR
 Glucose signalling 1833-P
 Glucose testing 853-P
 Glucose tolerance test 1296-P, 1375-P, 1749-P
 Glucose tolerance 58-OR, 226-OR, 359-OR, 379-OR, 1373-P, 1742-P, 1918-P, 2592-PO, 2601-PO
 Glucose toxicity 1695-P
 Glucose transport 1713-P, 1849-P
 Glucose uptake 1699-P
 Glucose variability 2314-PO, 2348-PO
 Glucose 145-OR, 158-OR, 281-OR, 292-OR, 327-OR, 420-P, 420-P, 523-P, 1221-P, 1353-P, 1915-P
 Glucose-6-phosphatase 2147-P
 Glucose-dependent insulinotropic polypeptide (GIP) 1741-P
 Glucose-induced insulin secretion 1752-P, 2157-P
 Glucose-induced neuronal damage 2583-PO
 Glucose-lowering therapies 2220-PO
 Glucose-regulated gene expression 42-OR
 Glucose-sensing receptor 2157-P
 Glucose-stimulated insulin secretion 1746-P
 Glucotoxicity 310-OR, 1843-P, 2103-P, 2176-P
 Glucotrack 859-P
 Glut1 expression 1699-P
 Glut2 216-OR
 Glut4 trafficking 2587-PO
 GLUT-4 translocation 1708-P, 1714-P
 Glut4 141-OR, 370-OR, 1678-P
 Glutamina dipeptide 2430-PO
 Gluteal adipose tissue 2090-P
 Glyburide 2484-PO
 Glyca 466-P, 1345-P
 Glycaemia 542-P, 1311-P
 Glycaemic control 691-P, 2375-PO
 Glycated albumin 1371-P
 Glycated hemoglobin 849-P, 1363-P, 2502-PO, 2530-PO
 Glycation end products 1273-P
 Glycation gap 400-P
 Glycation 421-P, 2176-P
 Glycemia 718-P, 726-P, 1523-P, 2329-PO
 Glycemic control benchmarks 1165-P
 Glycemic control without hypoglycemia 123-OR
 Glycemic control 258-OR, 323-OR, 612-P, 722-P, 738-P, 740-P, 783-P, 837-P, 852-P, 884-P, 1047-P, 1108-P, 1154-P, 1222-P, 1320-P, 1320-P, 1457-P, 1568-P, 1574-P, 1577-P, 2377-PO, 2542-PO, 2544-PO
 Glycemic excursions 835-P
 Glycemic index 739-P
 Glycemic indicators 1517-P
 Glycemic load counting 854-P
 Glycemic management after bariatric surgery 2041-P
 Glycemic measure 1360-P
 Glycemic progression 1373-P
 Glycemic remission 923-P
 Glycemic trait 1603-P, 1609-P
 Glycemic variability 80-OR, 472-P, 809-P, 848-P, 863-P, 1012-P, 1065-P, 2346-PO
 Glycemic 796-P
 Glyceryl trinitrate mediated dilation 492-P
 Glycogen synthase 228-OR
 Glycogen 1266-P
 Glycolysis 1828-P, 2585-PO
 Glyoxalase 38-OR, 1917-P
 Gnotobiotic mice 280-OR
 GPR120 2164-P
 GPR30 243-OR
 GPR40 1117-P, 1758-P, 2156-P, 2158-P, 2419-PO, 2680-PO
 GPR81 91-OR
 G-protein coupled receptors 2195-P
 Gray matter atrophy 1457-P
 GRB10 1724-P
 GRK2 713-P
 Group lifestyle balance 9-OR
 Group visits 1185-P
 Growth factors 1631-P
 Growth 1215-P
 GSH 2330-PO
 GSIS 45-OR, 2160-P, 2171-P
 GSK-3beta 46-OR
 Guideline implementation 1195A-P
 Guideline performance 1413-P
 Guidelines 2296-PO, 2434-PO
 Gum 701-P
 Gut bacteria 1040-P
 Gut flora 1977-P
 Gut hormones 1915-P
 Gut inflammation 177-OR
 Gut microbiome 1044-P, 1627-P
 Gut microbiota 100-OR, 177-OR, 1200-P
 Gut microflora 750-P
 Gut 374-OR
 GWAS of NHDL 1322-P
 GWAS 1598-P, 1603-P, 1610-P, 2554-PO
 GWA-studies 1589-P
 H2O2 2173-P
 HAPO 1299-P
 Hba1c \geq 9% 1094-P

- Hba1c role for diagnosis diabetes Vietnam 1366-P
Hba1c 166-OR, 419-P, 423-P, 499-P, 666-P, 689-P, 864-P, 902-P, 925-P, 1188-P, 1356-P, 1362-P, 1365-P, 1388-P, 1550-P, 2353-PO, 2442-PO, 2463-PO, 2498-PO, 2501-PO, 2543-PO
HCA2 92-OR
HDL apolipoproteins 2392-PO
HDL cholesterol 620-P
HDL functionality 627-P
HDL 421-P
HDL-C 453-P, 1349-P
Health belief 2298-PO
Health care costs 1189-P, 1190-P
Health care delivery 317-OR, 318-OR, 1151-P, 1169-P, 1182-P
Health care provider 319-OR
Health care resource allocation 1157-P
Health care transition 673-P
Health coaching 317-OR, 1182-P
Health disparities 620-P
Health education 702-P
Health literacy 757-P
Health outcomes 830-P
Health related quality of life 1166-P
Health systems 1386-P
Health utility analyses 2220-PO
Healthcare costs 570-P, 1167-P, 2441-PO
Healthcare goals 2489-PO
Healthcare utilization 24-OR, 254-OR, 1154-P, 1532-P
Healthy aging and longevity 1322-P
Healthy eating index 2010 737-P
Healthy eating 2467-PO
Healthy lifestyle skills 830-P
Healthy obese 1804-P, 2002-P, 2030-P
Healthy subjects 886-P, 889-P, 890-P, 893-P
Heaptic steatosis 1783-P
Heart failure 471-P, 476-P, 481-P, 1028-P, 1334-P, 1336-P, 1970-P
Heart rate variability 478-P, 730-P
Heart rate 1452-P
Heart 490-P, 1855-P
Heat shock protein 1867-P, 2015-P
Heel ulcer 661-P
Hematocrit 875-P
Hematopoietic progenitor Cells 596-P
Hematopoietic stem cell 124-OR, 351-OR
Hemodialysis 63-OR
Hemoglobin A1C 612-P, 856-P, 1154-P, 1390-P, 2234-PO, 2303-PO
Hemoglobin 400-P
Hepatic cirrhosis 1447-P
Hepatic extraction 1755-P
Hepatic fat 744-P
Hepatic fibrosis 1811-P, 2605-PO
Hepatic gluconeogenesis 1795-P
Hepatic glucose production 371-OR, 1683-P
Hepatic impairment 980-P
Hepatic insulin resistance 33-OR, 35-OR, 1730-P, 1768-P, 1799-P, 1811-P, 2079-P
Hepatic insulin sensitivity 744-P
Hepatic insulin signaling 1831-P
Hepatic lipid deposition, 1954-P
Hepatic lipid metabolism 1819-P
Hepatic mitochondrial function 1770-P
Hepatic steatosis 59-OR, 1686-P, 1773-P, 2656-PO
Hepatic 1786-P
Hepatocellular carcinoma 1789-P, 1913-P
Hepatocyte growth factor 2131-P
Hepatocyte nuclear factor 1-alpha 1615-P
Hepatokine 1267-P
Hepato-preferential action 886-P
Hepatosteatosi 1810-P
Hepg2 1794-P
Heritability 1584-P
Hesc 2116-P
Hgb A1c trajectory 1260-P
HGF 2101-P
HIF-1alpha 593-P, 1973-P
HIF2 alpha 188-OR
High density lipoprotein 1921-P
High fat diet 224-OR, 307-OR, 1606-P, 1618-P, 1741-P, 1754-P, 1757-P, 1982-P, 1990-P, 2104-P, 2139-P
High fat overfeeding 298-OR
High glucose 505-P, 2244-PO, 2685-PO
High glucose, adenosine 593-P
High HDL 627-P
High insulin dose 915-P
High intensity interval exercise 718-P
High normal hba1c 2446-PO
High risk 1501-P
High sensitive c-reactive protein 2651-PO
High-fructose corn syrup 1977-P
High-glucose 455-P
High-quality Imaging 1661-P
High-risk 1374-P
Hippocampus 2208-PO
Hirsutism 1549-P
Hispanic Americans 1348-P
Histology 1963-P
Histone acetylation 528-P
HLA in diabetes 2564-PO
HLA 271-OR, 1652-P
HM12460A 894-P, 895-P
HMG coa reductase inhibitors 1406-P
Hmga1 455-P
HMG-coa reductase inhibitor 477-P, 1787-P
HMW adiponectin 2040-P
HOMA IR 2527-PO
HOMA-β index 1018-P
Home blood pressure 431-P
Home study 233-OR
Home telemonitoring 833-P
Home visits 689-P
Home base health care 1194-P
Homocysteine metabolism 2553-PO
Homocysteine 1444-P
Hormone FGF21 1897-P
Hospital admission 2217-PO
Hospital hypoglycemia 2223-PO
Hospital mentoring 686-P
Hospital monitoring 868-P
Hospital quality 1145-P
Hospital readmission 1164-P, 2305-PO, 2469-PO, 2493-PO
Hospital stay 638-P
Hospital 700-P, 931-P, 1170-P, 2211-PO
Hospitalization 935-P, 958-P, 1160-P, 1424-P
Hospital-related hyperglycemia 1403-P
HOX genes 2090-P
HPLC 1367-P
HREC 593-P
Human adipocyte 2014-P
Human adipose beiging 2075-P
Human adipose tissue 1623-P, 2023-P
Human ADME 1080-P
Human beta cells 2190-P
Human insulin 1156-P
Human ips cells 2129-P
Human Islets 41-OR, 342-OR, 2105-P, 2688-PO
Human pancreatic islet 149-OR, 196-OR
Human primary keratinocytes 2290-PO
Human recombinant tissue Kallikrein-1 977-P
Human retinal microvascular endothelial cells 1131-P
Human skeletal muscle cells 229-OR, 1722-P
Human substrate metabolism 100-OR
Human 192-OR
Hybrid peptide 373-OR
Hydrogen sulfide 2253-PO
Hyper/hypoglycemia alert 2355-PO
Hyperandrogenism 1896-P
Hyperbaric oxygen therapy 590-P
Hyperbolic product 629-P
Hypercholesterolemia 1406-P
Hyperglycaemia in pregnancy 2531-PO
Hyperglycemia metabolism 310-OR
Hyperglycemia reversal 1635-P
Hyperglycemia 171-OR, 345-OR, 401-P, 850-P, 907-P, 1129-P, 1145-P, 1171-P, 1177-P, 1316-P, 1510-P, 1604-P, 1902-P, 2152-P, 2272-PO, 2337-PO, 2455-PO, 2464-PO, 2565-PO
Hyperglycemic clamp 1744-P
Hyperglycemic crisis 1433-P
Hyperglycemic emergencies 2517-PO
Hyperinsulinemia 1709-P, 1740-P, 1842-P
Hyperinsulinemic euglycemic clamp 1858-P, 2608-PO
Hyperkalemia 553-P, 1139-P
Hyperlipidemia 1173-P
Hyperlipidemic mice 1500-P
Hyperosmolar hyperglycemic state 2517-PO
Hypertension 426-P, 523-P, 831-P, 1052-P, 1054-P, 1437-P, 2229-PO
Hypertriglyceridemia 205-OR, 1819-P
Hypglycemia 1531-P
Hypoadiponectinemia 1725-P
Hypocholesterolemic agent 1352-P
Hypoglycaemia 2563-PO
Hypoglycaemia in community patients 2219-PO
Hypoglycaemia 396-P, 882-P, 1459-P, 2436-PO
Hypoglycemia prevalence 2222-PO
Hypoglycemia prevention 940-P
Hypoglycemia reduction 231-OR, 936-P, 2369-PO
Hypoglycemia unawareness 251-OR, 253-OR
Hypoglycemia 22-OR, 67-OR, 102-OR, 134-OR, 141-OR, 142-OR, 143-OR, 145-OR, 146-OR, 147-OR, 148-OR, 169-OR, 171-OR, 247-OR, 248-OR, 250-OR, 252-OR, 253-OR, 254-OR, 385-OR, 389-P, 391-P, 392-P, 393-P, 393-P, 397-P, 397-P, 398-P, 399-P, 401-P, 402-P, 403-P, 403-P, 405-P, 407-P, 408-P, 696-P, 733-P, 817-P, 847-P, 867-P, 888-P, 911-P, 915-P, 924-P, 1027-P, 1043-P, 1058-P, 1081-P, 1178-P, 1179-P, 1435-P, 2207-PO, 2208-PO, 2211-PO, 2212-PO, 2215-PO, 2216-PO, 2217-PO, 2218-PO, 2220-PO, 2221-PO, 2224-PO, 2226-PO, 2455-PO, 2684-PO
Hypothalamic signaling 1941-P
Hypothalamus 380-OR, 1833-P, 1901-P, 1919-P
Hypothyroidism 1238-P
Hypoxia 229-OR
IADPSG 1283-P, 1304-P, 1411-P
Ibgstar 834-P
IENFD 2273-PO
IGF binding proteins 1742-P
IGF-1 receptor 1716-P, 293-OR, 1907-P
IGF-2, nutrients 2182-P
IGT 1122-P, 1720-P, 2274-PO

- IL-1 489-P
 IL-6 1105-P
 Ileum 378-OR
 Imaging mass spectrometry 526-P
 Imaging 595-P, 2585-PO
 Imatinib 589-P
 Ineglimin 119-OR, 120-OR, 1067-P
 Immigrant 1204-P, 1430-P
 Immune protection 85-OR
 Immune function 2565-PO
 Immune mediators 48-OR
 Immune tolerance 1648-P
 Immunity 282-OR
 Immunization 2448-PO
 Immunoassay 1367-P
 Immunogenicity 70-OR, 1640-P
 Immunoglobulin G 1510-P
 Immunometabolism 284-OR
 Immunosuppression 345-OR
 Immunotherapy 124-OR, 174-OR
 Impaired fasting glucose 791-P, 1205-P, 1372-P
 Impaired glucose metabolism (IGM) 2007-P
 Impaired glucose regulation 2155-P, 2235-PO
 Impaired glucose tolerance 743-P, 1342-P, 1372-P, 1381-P, 1405-P, 1501-P, 2537-PO
 Implantable sensor 837-P
 Improved glycaemic control 2301-PO
 Improved self care behaviours 2301-PO
 Improvement in insulin sensitivity 2004-P
 Improvement of glucose tolerance 125-OR
 In vitro assay 1713-P
 In vivo 1822-P, 1975-P, 2145-P
 Incidence of diabetes 1052-P, 1403-P
 Incidence of DM 1416-P
 Incidence 167-OR, 787-P, 1251-P, 1370-P, 1376-P, 1414-P
 Incident diabetes 1373-P, 1401-P
 Incident type 2 diabetes 357-OR, 1292-P
 Incident 1360-P
 Increased attendance 667-P
 Incretin axis 283-OR
 Incretin effect 189-OR, 2607-PO
 Incretin hormones 189-OR, 1748-P, 1749-P
 Incretin like peptides 373-OR
 Incretin secretion 1908-P
 Incretin therapies 1438-P
 Incretin 160-OR, 1892-P, 1909-P, 1910-P, 2412-PO, 2417-PO
 Incretin-based drugs and insulin 1446-P
 Incretins 56-OR, 154-OR, 194-OR, 1825-P, 1900-P, 1911-P, 2102-P
 Indigenous population 1474-P, 1551-P
 Induced pluripotent stem cells 2022-P, 2138-P
 Infant feeding 168-OR
 Infected diabetic foot ulcer 638-P
 Inflammasome 312-OR, 756-P
 Inflammation 77-OR, 282-OR, 286-OR, 443-P, 444-P, 466-P, 487-P, 497-P, 509-P, 518-P, 529-P, 532-P, 561-P, 582-P, 1070-P, 1126-P, 1126-P, 1345-P, 1550-P, 1631-P, 1649-P, 1675-P, 1676-P, 1694-P, 1711-P, 1743-P, 1813-P, 1831-P, 1850-P, 1870-P, 1876-P, 1926-P, 1931-P, 1932-P, 1958-P, 1961-P, 1997-P, 2068-P, 2159-P, 2192-P, 2192-P, 2248-PO, 2514-PO, 2551-PO, 2639-PO, 2661-PO
 Inflammatory cytokines 1233-P, 2191-P, 2401-PO
 Inflammatory markers 163-OR, 433-P, 2659-PO
 Inflammatory signaling 2206-P
 Inflammation 2152-P
 Influenza 2448-PO, 2535-PO
 Information technology 1158-P
 Infusion algorithm 2444-PO
 Infusion set 887-P
 Inhaled insulin 127-OR, 128-OR
 In hospital insulin therapy 2375-PO
 In-hospital mortality 2217-PO
 Initial combination 150-OR
 Injectable 2380-PO
 Injection depth 131-OR
 Injection site warming 893-P, 957-P, 2371-PO
 Injections 2304-PO
 Innate cytokine 1647-P
 Innate immunity 284-OR
 Innervation 2128-P
 Inos 1138-P
 Inpatient costs 1177-P
 Inpatient diabetes care 1388-P
 Inpatient diabetes education 2305-PO
 Inpatient diabetes management 693-P, 2345-PO, 2451-PO
 Inpatient diabetes protocol 909-P
 Inpatient diabetes 686-P, 853-P, 1170-P
 Inpatient glucose management 2457-PO
 Inpatient glycemic control 911-P, 1145-P, 2307-PO, 2457-PO
 Inpatient hyperglycemia 5-OR, 700-P
 Inpatient subcutaneous insulin 1191-P
 Inpatient treatment 1191-P, 2444-PO
 Inpatient 1162-P, 1171-P, 2308-PO, 2455-PO
 Insulin resistance 1715-P, 2329-PO
 Insulin secretion 2170-P
 Insulin action 365-OR, 371-OR, 1700-P, 1726-P, 1728-P, 1753-P, 2078-P
 Insulin algorithms 1191-P
 Insulin analogues 442-P, 884-P, 1156-P, 1907-P
 Insulin antibodies 1566-P, 2221-PO
 Insulin autoantibody 1646-P
 Insulin biogenesis 2187-P
 Insulin clearance 121-OR
 Insulin combination 1060-P
 Insulin co-prescription 1020-P
 Insulin degludec 63-OR, 64-OR, 65-OR, 66-OR, 402-P, 402-P, 882-P, 888-P, 906-P, 925-P, 1179-P, 1241-P, 2360-PO
 Insulin degrading enzyme 1734-P
 Insulin delivery route 247-OR
 Insulin delivery system 951-P, 2372-PO
 Insulin detemir 916-P
 Insulin dose 847-P, 923-P, 1733-P, 2356-PO
 Insulin dosing 858-P, 917-P, 934-P
 Insulin glargine 67-OR, 389-P, 786-P, 892-P, 906-P, 916-P, 919-P, 928-P, 961-P, 970-P, 2357-PO
 Insulin granules 2144-P
 Insulin infusion 857-P, 933-P, 2223-PO
 Insulin injection 901-P, 957-P, 2371-PO
 Insulin intensification 1152-P, 1535-P, 1538-P
 Insulin NPH 932-P
 Insulin Peptide 1639-P
 Insulin Pharmacokinetics 2368-PO
 Insulin processing defect 2109-P
 Insulin protocols 2457-PO
 Insulin pump suspension 231-OR, 936-P, 940-P, 940-P
 Insulin pump therapy 832-P, 930-P, 958-P, 2367-PO
 Insulin pump 583-P, 674-P, 674-P, 819-P, 939-P, 945-P, 946-P, 1227-P, 1252-P, 1756-P, 2299-PO, 2377-PO, 2378-PO
 Insulin receptor deletion 315-OR
 Insulin receptor knockout 186-OR
 Insulin receptor signaling 990-P, 2590-PO
 Insulin receptor substrate 2 2111-P
 Insulin receptor 900-P, 1690-P, 1693-P, 1716-P, 1849-P
 Insulin regimens 922-P, 935-P, 2542-PO
 Insulin requirements 2092-P
 Insulin resistance in African Americans 1893-P
 Insulin resistance 36-OR, 37-OR, 39-OR, 59-OR, 60-OR, 90-OR, 121-OR, 182-OR, 184-OR, 188-OR, 202-OR, 224-OR, 225-OR, 227-OR, 230-OR, 277-OR, 291-OR, 296-OR, 307-OR, 366-OR, 367-OR, 369-OR, 376-OR, 494-P, 622-P, 670-P, 729-P, 751-P, 1023-P, 1068-P, 1121-P, 1196-P, 1201-P, 1206-P, 1210-P, 1212-P, 1213-P, 1215-P, 1235-P, 1315-P, 1331-P, 1345-P, 1355-P, 1357-P, 1382-P, 1396-P, 1466-P, 1473-P, 1492-P, 1518-P, 1519-P, 1550-P, 1564-P, 1587-P, 1594-P, 1604-P, 1616-P, 1628-P, 1664-P, 1665-P, 1670-P, 1672-P, 1673-P, 1678-P, 1681-P, 1682-P, 1684-P, 1688-P, 1692-P, 1694-P, 1695-P, 1697-P, 1706-P, 1707-P, 1710-P, 1717-P, 1720-P, 1723-P, 1727-P, 1731-P, 1750-P, 1754-P, 1771-P, 1773-P, 1780-P, 1792-P, 1793-P, 1798-P, 1804-P, 1818-P, 1831-P, 1836-P, 1843-P, 1848-P, 1854-P, 1858-P, 1873-P, 1876-P, 1878-P, 1881-P, 1886-P, 1920-P, 1934-P, 1936-P, 1947-P, 1969-P, 1973-P, 1979-P, 1980-P, 1985-P, 1996-P, 2009-P, 2015-P, 2019-P, 2032-P, 2033-P, 2053-P, 2062-P, 2080-P, 2089-P, 2125-P, 2145-P, 2165-P, 2285-PO, 2323-PO, 2359-PO, 2479-PO, 2503-PO, 2538-PO, 2554-PO, 2577-PO, 2586-PO, 2588-PO, 2594-PO, 2599-PO, 2600-PO, 2608-PO, 2657-PO, 2669-PO
 Insulin response 1846-P
 Insulin secretion 120-OR, 160-OR, 189-OR, 190-OR, 192-OR, 342-OR, 615-P, 728-P, 1082-P, 1355-P, 1355-P, 1397-P, 1558-P, 1702-P, 1753-P, 1762-P, 1766-P, 1908-P, 1920-P, 2151-P, 2151-P, 2153-P, 2156-P, 2158-P, 2164-P, 2165-P, 2174-P, 2178-P, 2179-P, 2184-P, 2195-P, 2404-PO, 2685-PO
 Insulin secretory capacity 1745-P
 Insulin self-administration 668-P
 Insulin sensitivity 29-OR, 61-OR, 95-OR, 96-OR, 119-OR, 187-OR, 239-OR, 295-OR, 615-P, 727-P, 735-P, 1019-P, 1558-P, 1570-P, 1622-P, 1677-P, 1745-P, 1745-P, 1772-P, 1841-P, 1851-P, 1874-P, 1956-P, 2286-PO, 2597-PO
 Insulin signaling genes 1599-P
 Insulin signaling pathways 1689-P
 Insulin signaling 47-OR, 89-OR, 136-OR, 141-OR, 290-OR, 294-OR, 372-OR, 1622-P, 1683-P, 1738-P
 Insulin storage 2676-PO
 Insulin therapy 132-OR, 134-OR, 668-P, 668-P, 690-P, 926-P, 1180-P, 2307-PO, 2439-PO
 Insulin titration 914-P
 Insulin transport 40-OR
 Insulin treatment 5-OR, 1141-P, 1309-P, 2432-PO
 Insulin uptake 1691-P
 Insulin 91-OR, 95-OR, 319-OR, 474-P, 476-P, 548-P, 581-P, 695-P, 885-P, 887-P, 887-P, 898-P, 1025-P, 1027-P, 1027-P, 1058-P, 1503-P, 1521-P, 1531-P, 1533-P, 1685-P, 1719-P, 1719-P, 1735-P, 1755-P, 1761-P, 1776-P, 1889-P, 1943-P, 2177-P, 2209-PO, 2243-PO, 2309-PO, 2373-PO, 2380-PO, 2395-PO, 2398-PO, 2405-PO, 2475-PO, 2480-PO, 2521-PO
 Insulinase 978-P
 Insulin-associated weight gain 973-P
 Insulin-degrading enzyme 978-P, 2580-PO
 Insulin-like growth factor-1 1265-P
 Insulin-producing cells 2126-P, 2130-P
 Insulin-secretagogues 2225-PO
 Insulin-variable number tandem repeats 1580-P
 Insulinitis 175-OR, 1633-P

- Insulysin 978-P
 Insupad 957-P, 2371-PO
 Insurance benefit design 24-OR
 Integrated care 1158-P
 Integrin 533-P, 1742-P, 1742-P, 1836-P, 1836-P
 Integrin-linked kinase 33-OR
 Intensive diabetes treatment 617-P
 Intensive insulin therapy 328-OR, 923-P
 Intensive insulin titration 839-P
 Intensive insulin treatment 2463-PO
 Interaction genetics and epigenetics 1623-P
 Interaction 1591-P
 Interesterified fat 1959-P
 Interference 876-P
 Interferon gamma 1648-P
 Interleukin-1 beta 2107-P
 Interleukin-6 polymorphism 575-P
 Intermittent fasting 1894-P
 Intermittent hypoxia 1694-P
 Internalization 900-P
 International registry 2541-PO
 International 703-P
 Internet blood glucose monitoring system (IBGMS) 842-P
 Internet intervention 260-OR, 842-P
 Internet-based 1259-P
 Interpersonal processes of care survey 804-P
 Interstitial glucose transport 838-P
 Intertia 1170-P
 Interval walking training 2316-PO
 Intervention 255-OR, 702-P, 1217-P, 1482-P
 Intestinal cancer 1690-P, 1693-P
 Intestinal glucose uptake 1693-P
 Intestinal tract 1922-P
 Intestinal 1704-P
 Intimal hyperplasia 502-P
 Intimal thickening 314-OR
 Intima-media thickness 0418-P, 434-P, 453-P, 456-P, 1236-P, 1444-P
 Intraabdominal surgery 1177-P
 Intracellular communication 1921-P
 Intradermal 2368-PO
 Intraductal viral infusion 199-OR
 Intramuscular adipocyte 1845-P
 Intramyocellular lipid 1841-P, 1862-P, 1866-P
 Intranasal insulin 1796-P
 Intraperitoneal 941-P
 Intrauterine growth restriction 1760-P
 Intrauterine growth retardation 1270-P
 Ipla2beta 48-OR, 2204-P
 Ipro 880-P, 2346-PO
 Ips cells 288-OR
 Ipsc 294-OR
 IRF4 88-OR
 Irisin 2065-P, 2078-P
 Iron load 2086-P
 Iron 1961-P
 IRS 305-OR
 IRS-1 501-P, 1682-P, 1684-P, 1724-P, 2593-PO
 IRS-2 knockout mice 1840-P
 IRS-2 47-OR, 106-OR
 Ischemia reperfusion 1865-P
 Ischemia 467-P, 644-P
 Ischemic foot 218-OR
 Ischemic tolerance 483-P
 Islet amyloid polypeptide 44-OR
 Islet amyloid 306-OR, 2107-P
 Islet arterioles 2205-P
 Islet autoimmunity 1578-P
 Islet beta-cell failure 2109-P
 Islet beta-cell 2095-P
 Islet cell stress 1657-P
 Islet cell transplantation 83-OR
 Islet co-culture 2126-P
 Islet development 2123-P
 Islet electrophoresis 841-P
 Islet endothelial cells 2198-P
 Islet epigenome 275-OR
 Islet factors 2198-P
 Islet function 1270-P
 Islet glucose cycling 2147-P
 Islet infiltration 48-OR
 Islet isolation 1662-P
 Islet physiology 303-OR
 Islet transplantation 79-OR, 80-OR, 84-OR, 85-OR, 86-OR, 343-OR, 348-OR, 1657-P, 1660-P, 2566-PO, 2567-PO, 2569-PO
 Islet 56-OR, 341-OR, 861-P, 1653-P, 1661-P, 2096-P, 2127-P, 2128-P, 2135-P, 2140-P, 2159-P, 2173-P, 2185-P, 2196-P, 2664-PO, 2679-PO
 Islet-depleted tissue 2137-P
 Islets of langerhans 2673-PO
 ISO guidelines 872-P
 Isotope tracer 1705-P
 Israel 1399-P
 IUGR 2120-P
 IV insulin infusion 924-P
 IVGTT 1766-P
 Jaffna district 1495-P
 Japanese outpatient 843-P
 Japanese 1481-P, 1610-P
 Jinlida 1793-P
 JNK 503-P, 528-P, 1933-P
 Joint mobility 642-P
 Jubilé 795-P
 Kaempferol 1969-P
 KATP channel 2179-P
 KCNJ11 1619-P
 Keichiro 510-P
 Ketoacidosis 1565-P
 Ketogenesis 1059-P, 1830-P
 Ketogenic diet 2321-PO
 Ketosis prone diabetes 151-OR, 2180-P, 2183-P, 2286-PO, 2507-PO
 Kidney disease 558-P, 1576-P
 Kidney dysfunction 2263-PO
 Kidney function 8-OR, 513-P, 513-P
 Kidney outcomes 1450-P
 Kidney transplant 2258-PO
 Kidney 512-P, 523-P, 534-P
 Kinetics 300-OR
 Kkay mice 1734-P
 Knowledge 692-P, 697-P, 2295-PO
 Korea 1109-P, 1435-P, 2532-PO
 Koshigaya 1015-P
 K-ras, menin, MAPK, rassf1a 201-OR
 Kv channel 2150-P
 Labile hemoglobin 849-P
 Laboratory score 1393-P
 Lactation 145-OR, 357-OR, 1292-P, 2049-P
 LADA 564-P, 1579-P, 2564-PO
 Lancing 2354-PO
 Language barrier 1430-P
 Laparoscopic sleeve gastrectomy 2017-P
 Large longitudinal cohort study 1330-P
 Late elderly 477-P
 Late snacking 947-P
 Latent autoimmune diabetes in adults 152-OR, 1529-P, 1579-P
 Latent class analysis 1540-P
 Later stage of type 2 diabetes 2419-PO
 Latina women 709-P
 Latino health 2520-PO
 Latino peer coach 1164-P
 Latino 667-P, 763-P
 L-carnitine 2616-PO
 L-cysteine 2330-PO
 LDI flare 112-OR
 Ldiflare technique 587-P
 LDL 381-OR
 LDL-C lowering 614-P
 LDL-cholesterol 1572-P, 2237-PO
 LEA rat 1976-P
 Left ventricular dysfunction 4-OR, 584-P, 1148-P
 Left-handedness 629-P
 Length of hospital stay 22-OR
 Length of stay 2469-PO
 Leptin deficiency 2464-PO
 Leptin signaling 1901-P
 Leptin 143-OR, 282-OR, 1144-P, 1882-P, 1916-P, 2480-PO, 2491-PO, 2642-PO, 2655-PO
 Leu72Met polymorphism 2261-PO
 Leucine and metformin synergy 1108-P, 1797-P
 Leucine kinetics 302-OR
 Leukotrienes 352-OR
 Life expectancy 1563-P
 Life tables 1563-P
 Lifestyle barriers 2340-PO
 Lifestyle change program 339-OR
 Lifestyle factors 1461-P
 Lifestyle intervention 19-OR, 262-OR, 363-OR, 669-P, 765-P, 791-P, 816-P, 1517-P, 1520-P, 1545-P, 2067-P, 2316-PO, 2341-PO, 2645-PO
 Lifestyle modification 727-P, 1110-P
 Lifestyle 74-OR, 829-P, 1591-P, 2477-PO
 Lifetime risk 1487-P
 Light intensity 2592-PO
 Limited resource 611-P
 Linagliptin 1025-P, 1026-P, 1048-P, 1060-P, 1071-P, 1081-P, 2405-PO, 2583-PO
 Lipasin 618-P
 Lipid accumulation 461-P, 1957-P
 Lipid deposition 1805-P
 Lipid lowering agents 2525-PO
 Lipid markers (ldlc, apob, nonhdlc, TG:hdlc) 450-P
 Lipid metabolism 618-P, 1621-P, 1794-P, 1797-P, 1868-P
 Lipid parameter 1042-P
 Lipid peroxidation 1987-P, 2194-P
 Lipid reduction, statins, guidelines 628-P
 Lipid sensing 1919-P
 Lipid targets 2237-PO
 Lipids 163-OR, 624-P, 1234-P, 1235-P, 1235-P, 1322-P, 1813-P, 1870-P, 2122-P, 2434-PO, 2647-PO
 Lipocalin-2 662-P
 Lipodystrophy 632-P, 1493-P, 1587-P, 2655-PO
 Lipogenesis 184-OR, 1784-P, 2604-PO
 Lipohypertrophy 865-P
 Lipoic acid synthase 1624-P
 Lipolysis 92-OR, 1882-P, 1928-P
 Lipoprotein heterogeneity 1331-P
 Lipoprotein lipase 244-OR, 1856-P
 Lipoprotein (a) 468-P, 629-P
 Lipoproteins 617-P, 1207-P
 Liposcience insulin resistance score 2230-PO
 Lipotoxicity 1219-P, 2154-P, 2680-PO
 Lipotoxicity 2174-P
 Liraglutide 64-OR, 65-OR, 66-OR, 97-OR, 331-OR, 376-OR, 952-P, 965-P, 969-P, 973-P, 974-P, 984-P, 985-P, 996-P, 999-P, 1006-P, 1014-P, 1017-P, 1020-P, 1106-P, 1714-P, 1943-P, 2027-P, 2058-P,

- 2388-PO, 2390-PO, 2395-PO, 2396-PO, 2488-PO, 2490-PO
 Lispro 962-P
 Lithospermic acid B 531-P
 Liuwei dihuang 1140-P
 Liver cirrhosis 1365-P, 2607-PO
 Liver disease 1447-P, 1554-P
 Liver energy metabolism 1796-P
 Liver enzymes 1800-P
 Liver fat content 1778-P
 Liver fat 61-OR
 Liver function tests 1092-P
 Liver glucokinase 1803-P
 Liver receptor homologue-1 735-P
 Liver transplant recipients 2571-PO
 Liver 37-OR, 122-OR, 287-OR, 292-OR, 710-P, 710-P, 1488-P, 1621-P, 1719-P, 1769-P, 1776-P, 1785-P, 1809-P, 1813-P, 1835-P, 1925-P, 2673-PO
 Lixisenatide 332-OR, 966-P, 971-P, 987-P, 989-P, 990-P, 991-P, 992-P, 1012-P, 1017-P, 1018-P
 Long acting insulin 1732-P
 Long duration type 1 538-P
 Long non coding RNA 597-P, 1270-P
 Long-acting exendin-4 1009-P
 Long-acting insulin analogue 2360-PO
 Long-acting 1005-P
 Long-chain n-3 fatty acids 58-OR
 Longevity 1112-P
 Longitudinal 1330-P, 1573-P
 Long-term effectiveness 1006-P
 Long-term glycemic control 1446-P
 Long-term survival 348-OR
 Long-term 964-P
 Look AHEAD 19-OR
 Lorcaserin 99-OR, 2038-P, 2039-P
 Loss of function 633-P
 Low birth weight 298-OR
 Low grade inflammation 374-OR
 Low immunogenicity 1009-P
 Low salt diet 1886-P
 Low-carbohydrate diet 2322-PO
 Lower extremity arterial disease 3-OR
 Lower urinary tract symptoms 2336-PO
 Lower-extremity amputation 636-P
 Low-income country 2537-PO
 LP-IR 1196-P
 Lppla2 2023-P
 LPS 1832-P
 LR-90 1143-P
 LRG1 414-P
 LUBAC 89-OR
 Lung function 1448-P, 2621-PO
 LY2963016 insulin glargine product 68-OR, 69-OR, 70-OR, 889-P, 890-P, 891-P
 Ly6C 1974-P
 Lycopene 1932-P
 M1/M2 macrophage 306-OR
 Macroangiopathy 623-P, 2233-PO
 Macronutrient 1468-P
 Macrophage polarization 1651-P
 Macrophage 178-OR, 279-OR, 286-OR, 369-OR, 1630-P, 1631-P, 1641-P, 1654-P, 1656-P, 1665-P, 1665-P, 1792-P, 2586-PO
 Macrosomia 1268-P
 Macro vascular complications 441-P, 1533-P
 Macro vascular risk 1330-P, 1446-P
 Mafa 2116-P
 MAGE 1197-P
 Magnetic resonance imaging 2091-P
 Magnetic resonance spectroscopy 560-P, 1866-P, 2008-P
 Magnetic resonans imaging 118-OR
 Magnolia 1957-P
 Maintenance therapy 553-P
 Major adverse cardiac events 2441-PO
 Major amputations 653-P
 Malonyl-coa 1868-P
 Mammals 516-P
 Managed care 1184-P
 Management 2442-PO
 MAPK signaling 716-P
 MARD 846-P
 Marital status 1515-P
 Marker 1415-P, 1417-P
 Mass spectrometry 1208-P, 2196-P
 Maternal diabetes 1262-P, 1558-P, 2480-PO
 Maternal environment 1806-P
 Maternal exercise 717-P
 Maternal glucose 1484-P
 Maternal glycemia and obesity 211-OR, 1264-P
 Maternal obesity 1271-P
 Mathematical model 1803-P
 Mathematical modeling 160-OR, 2587-PO
 Matsuda index 1357-P
 Mature adipocytes 1955-P
 MCP-1 2287-PO, 2625-PO
 Meal frequency 299-OR, 746-P
 Meal size 299-OR
 Meals 62-OR, 943-P
 Mean amplitude of glycemic excursions 472-P
 Mechanosensing 1981-P
 Media 782-P
 Mediator 779-P
 Medicaid claims analysis 1532-P
 Medicaid 687-P, 688-P
 Medical costs 2437-PO
 Medical education 1193-P
 Medical expenditure panel survey 1556-P
 Medical fast 2323-PO
 Medical nutrition therapy 751-P, 1478-P
 Medical risk model 1157-P
 Medication adherence 676-P, 758-P, 822-P, 1542-P, 2339-PO
 Medication initiation/escalation 2513-PO
 Medication therapy 2443-PO
 Medication utilization 1160-P
 Mediterranean diet 1482-P
 Melanocortin signaling 1902-P
 Melanocortin-4 receptor 712-P
 Memory 1231-P
 Mendelian randomization 1443-P
 Mental health 723-P, 763-P, 763-P, 784-P, 785-P, 2472-PO
 Menu plan 753-P
 Mesangial cells 514-P, 2248-PO
 Mesenchymal stem cells 649-P
 Mesenteric adipose tissue 2575-PO
 Meta-analysis 57-OR, 515-P, 515-P, 722-P, 820-P, 981-P, 1107-P, 1378-P, 1379-P, 1380-P, 1438-P, 2415-PO
 Metaanalysis 1337-P
 Metabioc syndrome 1626-P
 Metabochip 274-OR
 Metabolic abnormalities 1324-P
 Metabolic adaptation 375-OR
 Metabolic control 694-P, 794-P, 926-P, 1317-P, 1317-P, 2425-PO
 Metabolic disease 1216-P
 Metabolic disorders 2534-PO
 Metabolic efficiency 1966-P
 Metabolic fingerprinting 2069-P
 Metabolic flexibility 2056-P
 Metabolic flux 2604-PO
 Metabolic fluxes 2178-P
 Metabolic health 1310-P
 Metabolic parameter 1042-P, 1460-P
 Metabolic profile 621-P
 Metabolic programming 223-OR
 Metabolic risk factors 1257-P
 Metabolic risk 1507-P
 Metabolic stress 1701-P
 Metabolic surgery 2004-P
 Metabolic syndrome 261-OR, 436-P, 451-P, 464-P, 480-P, 614-P, 790-P, 993-P, 1153-P, 1208-P, 1387-P, 1399-P, 1408-P, 1412-P, 1474-P, 1477-P, 1490-P, 1490-P, 1589-P, 1629-P, 1852-P, 1893-P, 2032-P, 2033-P, 2232-PO, 2289-PO, 2324-PO, 2348-PO, 2478-PO, 2502-PO, 2634-PO, 2638-PO, 2641-PO, 2651-PO, 2652-PO
 Metabolically health 2042-P
 Metabolically healthy obese 78-OR, 1214-P, 2025-P, 2036-P, 2641-PO
 Metabolically unhealthy lean phenotype 2025-P
 Metabolism 288-OR, 1064-P, 1832-P, 2087-P
 Metabolomics 49-OR, 211-OR, 413-P, 1208-P, 1212-P, 1264-P, 1268-P, 1268-P, 1369-P, 1372-P, 1381-P, 1586-P, 1938-P, 1938-P, 2428-PO
 Metagenomic sequencing 2000-P
 Metallothionein 411-P
 Metformin and atherogenesis 1689-P
 Metformin 265-OR, 329-OR, 334-OR, 416-P, 467-P, 1044-P, 1066-P, 1087-P, 1301-P, 1428-P, 1428-P, 1596-P, 1779-P, 1810-P, 1862-P, 1991-P, 2166-P, 2407-PO, 2437-PO, 2484-PO, 2505-PO, 2555-PO, 2593-PO
 Methyl donor deficiency 1692-P
 Methylation 1611-P
 Methylglyoxal 38-OR, 115-OR, 421-P, 586-P, 2176-P
 Methylsulfonylmethane 1129-P
 Metreleptin 1493-P
 Metrics tracking 320-OR
 Metrics 1449-P
 Mexican American 277-OR, 1414-P
 Mice 243-OR, 1969-P
 Microalbuminuria 1125-P
 Microaneurysms 353-OR
 Microangiopathy 218-OR, 2283-PO
 Microarray 111-OR, 515-P
 Microbiome 1938-P, 1939-P, 2000-P
 Microbiota transplantation 1937-P
 Microbiota 280-OR, 1743-P, 2085-P
 Microcirculation 1837-P
 Microencapsulation 85-OR
 Micro fluidic device 2181-P
 Microfluidics 1661-P, 2679-PO
 Micro needle Patch 1007-P
 Microma 103-OR, 486-P, 1616-P, 1620-P, 2009-P, 2090-P, 2106-P, 2114-P, 2114-P
 Micromas 1612-P, 1718-P, 1718-P, 2119-P
 Micro vascular complication 441-P, 608-P, 658-P, 863-P, 1423-P, 2051-P
 Micro vascular reactivity 410-P
 Microvascular 354-OR, 542-P
 Microvasculature 1848-P
 Middle school students 830-P, 2458-PO
 Middle-aged and older adults 704-P
 Midkine 2588-PO
 Midlevel providers 318-OR
 Migrant 1434-P
 Mild and severe hypoglycemia 478-P
 Mild hypoglycemia 395-P
 Milk 1463-P

- Mindfulness 783-P
 Minimal psychological intervention 704-P
 Mir-200b 597-P, 599-P, 1262-P
 Mirna 314-OR, 487-P, 651-P, 2193-P, 2559-PO
 Missed dose 2337-PO
 Mitigation of oxidative stress 53-OR
 Mitiglinide 1091-P
 Mitochondria 119-OR, 287-OR, 288-OR, 292-OR, 447-P, 519-P, 594-P, 625-P, 1067-P, 1645-P, 1673-P, 1701-P, 1729-P, 1737-P, 1859-P, 1860-P, 1861-P, 1951-P, 1985-P, 1987-P, 2062-P, 2318-PO, 2580-PO
 Mitochondrial dysfunction 1396-P
 Mitochondrial fission 1685-P
 Mitochondrial function 1624-P, 1841-P, 1841-P, 1858-P, 2616-PO
 Mitochondrial permeability transition opening 1788-P
 Mitochondrial proteins 1955-P
 Mitochondrial pyruvate carrier 1746-P
 Mitochondrial TCA cycle 1818-P
 Mitochondrial uncoupling 34-OR
 Mitophagy 1860-P
 Mitral flow 4-OR
 Mixed methods R=research 761-P
 MMP-9 662-P
 Mobile health 397-P, 881-P
 Mobile technology 10-OR
 Model predictive control 942-P
 Model 2368-PO
 Moderate physical exercise 730-P
 MODY 135-OR, 1069-P, 1358-P, 1391-P, 1418-P, 1581-P
 Molecular mechanisms 1950-P
 Monitoring 799-P
 Monocyte 456-P, 529-P, 1909-P
 Monogenic diabetes 1581-P
 Monotherapy 264-OR, 1083-P, 2403-PO
 Mood disorders 563-P
 Morbid obesity 1552-P, 2073-P, 2083-P, 2656-PO
 Mortality after DM 1416-P
 Mortality rates 249-OR
 Mortality 98-OR, 147-OR, 221-OR, 335-OR, 384-OR, 392-P, 393-P, 403-P, 482-P, 539-P, 539-P, 636-P, 0638-P, 1337-P, 1340-P, 1341-P, 1516-P, 2048-P, 2207-PO, 2219-PO, 2263-PO, 2499-PO
 Mosaic observational cohort study 1535-P
 Mosaic 804-P, 1538-P, 2539-PO
 Motivation 679-P
 Mouse model 1772-P
 Mouse skeletal muscle cell 1714-P
 MRI 2656-PO
 Mrna translation 350-OR
 MSC coculture 2202-P
 Msrebp-1 2204-P
 MST2 1663-P
 MTHFR 2553-PO
 Mtor complex 289-OR
 Mtor 94-OR, 1656-P, 2114-P, 2120-P, 2186-P
 Mtorc1 2188-P
 MUFA 744-P
 Multidetector computed tomography 2042-P
 Multi-disciplinary teams 2449-PO
 Multifactorial intervention 1455-P
 Multifactorial target control 605-P
 Multifunctional peptide 374-OR
 Multi-layer nano encapsulation 342-OR
 Multi-national 1535-P
 Multiple daily insulin injections 270-OR
 Munc18b 304-OR
 Munc18c 2149-P
 Muscle atrophy 1872-P
 Muscle blood flow 1853-P
 Muscle cells 1737-P
 Muscle fat 736-P
 Muscle glucose uptake 1683-P, 1853-P
 Muscle metabolism 1864-P
 Muscle micro vascular perfusion 376-OR
 Muscle microvasculature 1838-P
 Muscle oxidative phosphorylation 1857-P
 Muscle progenitors 1845-P
 Muscle remodeling 1852-P
 Muscle strength 1318-P
 Muscle sympathetic nerve activity 1030-P
 Muscle 1584-P, 1738-P, 1849-P, 1851-P
 Mutant INS-gene-induced Diabetes of Young 2169-P
 Mutants 1580-P
 Mutation 135-OR, 136-OR, 1619-P, 2600-PO
 Myeloperoxidase 2241-PO
 Myf5 cre 186-OR
 Myocardial function 297-OR
 Myocardial infarction 484-P, 488-P, 1353-P, 2499-PO
 Myokines 1850-P, 2035-P
 Myosteatorsis 2037-P
 MYTH 1736-P
 N-3 polyunsaturated fat 748-P
 NAD metabolism 524-P
 NAFLD 359-OR, 1134-P, 1402-P, 1781-P, 1784-P, 1792-P, 1801-P, 1812-P, 1817-P, 1821-P, 2285-PO
 Naltrexone bupropion 1046-P
 Naltrexone 391-P
 NAMPT 2159-P
 Nanotechnology 595-P
 Naoko 510-P
 NASH 1447-P, 1506-P, 1789-P
 NAT2 2547-PO
 Natriuretic peptide 37-OR, 1346-P
 Naturally occurring type 2 diabetes 123-OR
 Near-normoglycemic remission 151-OR
 Neck circumference 2478-PO
 Needle phobia 685-P
 Neighborhood 1324-P
 Neighborhood walkability 76-OR, 383-OR
 Neogenesis 191-OR, 2146-P
 Neonatal abdominal adipose tissue 1198-P
 Neonatal adiposity 1484-P
 Neonatal diabetes 2185-P
 Nephropathy 50-OR, 511-P, 513-P, 522-P, 533-P, 536-P, 538-P, 546-P, 699-P, 1443-P, 1453-P, 2239-PO, 2260-PO, 2264-PO, 2282-PO, 2405-PO
 NERP-4 1889-P
 Nerve conduction studies 2280-PO
 Nerve dysfunction 113-OR
 Nesfatin-1 1944-P, 2073-P
 Network meta-analysis 335-OR, 399-P, 399-P
 Networking 1259-P
 Neulasta 173-OR, 1643-P
 Neural tube defects 215-OR, 1262-P
 Neuritin expression 2272-PO
 Neuroglucopenia 1901-P
 Neuromedin U 1975-P
 Neuronal hormone 375-OR
 Neuronal regeneration 2284-PO
 Neuropathic foot 218-OR
 Neuropathy 114-OR, 118-OR, 561-P, 564-P, 564-P, 582-P, 583-P, 721-P, 2276-PO, 2278-PO, 2282-PO
 Neuropeptides 1941-P
 Neurovascular measurements 641-P
 Newborn insulin secretion 2119-P
 Newcomer insulin granules 304-OR
 Newly diagnosed diabetes by OGTT 1-OR
 Newly diagnosed diabetes 1175-P
 Newly diagnosed type 2 diabetes 150-OR
 New-onset diabetes 1124-P
 New-user design 1524-P
 NF kappa-B 2204-P
 Nfkb inhibition 1872-P
 NF-kb 89-OR
 NHANES 828-P, 1216-P
 Niacin 1823-P
 Nicotine 818-P, 1757-P
 Nitric oxide 293-OR, 2191-P, 2199-P
 Nitrix oxide 2197-P
 NLRP3 inflammasome 110-OR, 1654-P
 N-methyl-D-aspartate antagonists 1062-P
 Nocturnal hypoglycemia 398-P, 402-P, 944-P, 2214-PO
 NOD mice 199-OR, 1045-P, 1632-P, 1635-P, 1648-P, 2096-P, 2562-PO
 NODAT 1659-P
 Non alcoholic fatty liver disease 1815-P
 Non-diabetic 1403-P
 Non HDL cholesterol 1412-P
 Non human primates 1744-P, 1993-P, 2167-P, 2577-PO, 2608-PO
 Non invasive glucose monitoring 859-P
 Non-alcoholic fatty liver disease 34-OR, 630-P, 1201-P, 1537-P, 1788-P, 1799-P, 1994-P, 2007-P, 2011-P, 2024-P, 2084-P, 2415-PO, 2611-PO
 Nonalcoholic steatohepatitis 1808-P, 1959-P, 1962-P
 Noncodingrna 314-OR
 Non-diabetic population 1363-P
 Non-esterified eicosapentaenoic acid 1473-P
 Non-esterified free fatty acids 1823-P
 Non-fasting plasma glucose 1385-P
 Non-HDL Cholesterol 2237-PO
 Non-insulin treated type 2 diabetes 14-OR, 678-P
 Non-invasive vascular assesment 634-P
 Non-laboratory score 1393-P
 Non-severe hypoglycemic event 394-P
 Norfolk QOL-DN 2271-PO
 Normal glucose 1517-P
 Normal osmolar hyperglycemic state 2517-PO
 Normoglycemia 1332-P
 Notch 525-P
 Novel ectopic transplantation site 2569-PO
 Novel treatment 125-OR
 NPC1L1 1924-P
 NPH insulin 928-P
 Npod 2132-P
 Nrf2 507-P, 1633-P, 1651-P, 1769-P, 1887-P
 NSTEMI 1-OR
 Nuclear magnetic resonance 1415-P, 1417-P, 2604-PO
 Nuclear magnetic resonance-determined lipoprotein 1572-P
 Nuclear medicine 2013-P
 Nuclearcytoplasmic transport of foxo1 109-OR
 Nucleobindin-2 1944-P
 Nur77 1992-P
 Nurse, diabetes mellitus, type 2 1188-P
 Nursing home 132-OR
 Nutrition education 1475-P
 Nutrition knowledge 2467-PO
 Nutrition 258-OR, 296-OR, 743-P, 749-P, 788-P, 1688-P
 Nutritional deficiency 2057-P
 Nutritional epidemiology 1280-P
 Nutritional programming 1935-P
 Obese adolescents 1200-P
 Obese db/db mice 1945-P
 Obese patients with Type 1 diabetes 2004-P

- Obese phenotypes 2030-P
 Obese pregnant women 1314-P
 Obesity and diabetes related traits 1623-P
 Obesity and insulin resistance 245-OR
 Obesity animal models 1956-P, 2628-PO
 Obesity dependent mechanisms 2003-P
 Obesity in children 1213-P, 2462-PO
 Obesity indices 2533-PO
 Obesity insulin resistance 2018-P
 Obesity paradox 2048-P
 Obesity 76-OR, 87-OR, 88-OR, 96-OR, 97-OR, 98-OR,
 99-OR, 101-OR, 125-OR, 157-OR, 158-OR,
 161-OR, 162-OR, 185-OR, 214-OR, 223-OR,
 240-OR, 241-OR, 242-OR, 246-OR, 279-OR,
 368-OR, 382-OR, 459-P, 756-P, 831-P, 1016-P,
 1111-P, 1126-P, 1204-P, 1211-P, 1212-P, 1219-P,
 1237-P, 1279-P, 1311-P, 1409-P, 1443-P, 1451-P,
 1688-P, 1697-P, 1719-P, 1769-P, 1783-P, 1825-P,
 1839-P, 1870-P, 1930-P, 1931-P, 1933-P, 1936-P,
 1939-P, 1958-P, 1959-P, 1960-P, 1962-P, 1967-P,
 1968-P, 1970-P, 1974-P, 1977-P, 1979-P, 1982-P,
 1985-P, 1986-P, 1988-P, 1993-P, 1996-P, 1998-P,
 2010-P, 2011-P, 2016-P, 2017-P, 2020-P, 2024-P,
 2026-P, 2027-P, 2029-P, 2031-P, 2038-P, 2039-P,
 2042-P, 2044-P, 2045-P, 2046-P, 2047-P, 2052-P,
 2053-P, 2056-P, 2057-P, 2058-P, 2061-P, 2063-P,
 2066-P, 2067-P, 2069-P, 2070-P, 2071-P, 2072-P,
 2074-P, 2079-P, 2085-P, 2086-P, 2087-P, 2089-P,
 2091-P, 2092-P, 2112-P, 2471-PO, 2491-PO,
 2586-PO, 2588-PO, 2629-PO, 2631-PO, 2632-PO,
 2634-PO, 2635-PO, 2636-PO, 2639-PO, 2646-PO,
 2657-PO, 2659-PO, 2661-PO
 Obesity-induced diabetes 1966-P
 Obesity-onset 1552-P
 Obstetric complications 1309-P
 Obstructive sleep apnea 443-P, 1723-P, 2026-P,
 2029-P, 2526-PO, 2599-PO
 Occludin 1131-P
 OCT2 1066-P
 Ocular complications in diabetes 610-P
 Offloading 220-OR, 222-OR, 650-P
 Offspring birth weight 1281-P
 Offspring 1982-P
 OGT 2148-P
 OGTT 358-OR, 430-P, 1210-P, 1405-P, 1537-P, 1659-P,
 1766-P, 2347-PO
 Older adults 268-OR, 821-P, 1176-P, 1317-P, 1317-P,
 1319-P, 1319-P
 Older people and ambulance call outs 2219-PO
 Oleate 1829-P
 Oleic acid 1827-P
 Olfactory dysfunction 1323-P
 Oligomenorrhea 1549-P
 Olmesartan 1526-P
 Omarigliptin 1080-P
 Omega 3 fatty acids 59-OR, 1815-P, 1861-P, 1968-P
 Omentin 452-P, 462-P, 2648-PO
 Omentum adipose tissue 2575-PO
 Once weekly 1010-P
 Once-weekly dosing 2385-PO
 Online diabetes education 703-P
 Online diabetes management 842-P
 Online glucose prediction 2355-PO
 Open access clinic 23-OR
 Opioid receptor 148-OR
 Optimal A1c cutoff value 1395-P
 Optimized treatment regimes 1823-P
 ORAI channels 505-P
 Oral antidiabetes drugs 1107-P
 Oral antidiabetes therapy 1089-P
 Oral anti-diabetic agents 2408-PO
 Oral antihyperglycemic agents 2522-PO
 Oral contraceptive 2383-PO
 Oral fat load 1070-P
 Oral GLP-1 155-OR, 156-OR
 Oral glucose tolerance test 1355-P, 1371-P, 1410-P,
 2036-P
 Oral health 1548-P, 1577-P
 Oral hygiene 1548-P
 Oral hypoglycemic agents 1614-P
 Oral Insulin 956-P, 2411-PO
 Oral 701-P, 1062-P
 Orchiectomy 1885-P
 Orexin 39-OR, 142-OR
 ORIGIN 542-P
 ORMD-0801 2411-PO
 Oscillations of insulin 1767-P
 OSM 2595-PO
 Osteoblast 2287-PO
 Osteocalcin 424-P, 496-P, 1402-P, 1875-P, 1900-P
 Osteogenic switch 500-P
 Osteomyelitis 639-P, 2291-PO
 Osteoporosis 1127-P, 1458-P, 1543-P, 1562-P
 Osteoprotegerin 424-P, 425-P, 569-P
 Outcomes 648-P, 1282-P, 1285-P, 1285-P, 1304-P
 Outpatient trial 954-P
 Outreach program 1195A-P
 Over nutrition 2068-P
 Overfeeding 1873-P
 Overnight 233-OR
 Overweight 162-OR, 2471-PO
 Ovulation 1569-P
 OX40L 1637-P
 Oxidative damage 440-P
 Oxidative stress 178-OR, 230-OR, 245-OR, 503-P,
 511-P, 520-P, 521-P, 527-P, 547-P, 578-P, 848-P,
 1053-P, 1476-P, 1687-P, 1770-P, 1793-P, 1965-P,
 2106-P
 Oxidized low density lipoprotein 2242-PO
 Oxidized LDL 2023-P
 OXPHOS 594-P
 Oxygen consumption 2161-P, 2580-PO
 Oxytocin 444-P, 1149-P
 P110a 1846-P
 p16lnk4a 203-OR
 P2Y receptor 2150-P
 P38 MAPK 209-OR, 1885-P
 P53 apoptosis 508-P
 Pacific Islanders 2645-PO
 PAID 1 824-P
 Pain 562-P, 582-P, 1128-P, 1146-P, 1429-P, 2354-PO
 Painful diabetic neuropathy (PDN) 570-P, 585-P
 PAK1 2103-P
 Palmitic acid 1827-P
 PAN PPAR 1084-P
 Pancreas cancer 1491-P
 Pancreas structure 2094-P
 Pancreas transplantation 81-OR, 82-OR
 Pancreas volume 2094-P
 Pancreas 154-OR, 195-OR, 966-P, 2124-P, 2132-P,
 2683-PO
 Pancreatic beta cells 46-OR, 2197-P, 2680-PO
 Pancreatic differentiation 2138-P
 Pancreatic fat content 835-P
 Pancreatic islet composition 204-OR
 Pancreatic islets 1072-P, 2161-P, 2168-P
 Pancreatic pathology 175-OR
 Pancreatic triglyceride (ptg) 193-OR
 Pancreatic β -cell mass 41-OR, 1117-P
 Pancreatitis 1438-P, 1491-P, 1491-P
 Paracrine interactions 2687-PO
 Parasympathetic innervation 1945-P
 Parasympathetic nerve activity 1000-P
 Parents 768-P
 Path analysis 2334-PO
 Pathophysiology of type 2 diabetes 2082-P
 Pathophysiology 1397-P, 1398-P, 1748-P
 Patient activation, measure 1194-P
 Patient attribution 18-OR
 Patient education 681-P
 Patient navigation 671-P
 Patient reported outcomes 2393-PO
 Patient simulation 322-OR
 Patient-centered 677-P, 683-P, 706-P
 Patient-provider relationships 803-P
 Patient-reported outcomes 979-P, 2521-PO
 Patients and pancreas survival 82-OR
 Patients' education 851-P
 Patterns of glucose variability 877-P
 PAX4 135-OR, 1607-P, 2118-P, 2121-P, 2556-PO
 PC1/3 1891-P, 2399-PO
 PCAF 309-OR
 PCOS 968-P, 2018-P
 PDH 625-P
 PDK 291-OR
 PDK4 1773-P
 PDX1 46-OR, 2172-P
 Pediatric diabetes 626-P, 880-P
 Pediatric exercise 2462-PO
 Pediatric obesity 1257-P
 Pediatric T2D 163-OR, 164-OR
 Pediatric type 1 diabetes 759-P, 799-P, 1241-P
 Pediatrics 161-OR, 552-P, 760-P, 1202-P, 1234-P,
 1238-P, 1239-P, 1243-P, 1253-P, 1258-P, 1497-P,
 1499-P, 1504-P
 Peer support 256-OR, 678-P, 772-P, 792-P
 Peer 677-P
 Pen injector 2389-PO
 PEPCCK 1617-P
 Peptide treatment 1016-P, 1019-P
 Peptides 2392-PO
 Perceived social support 804-P, 2299-PO
 Perceptions 680-P
 Performance evaluation 860-P
 Performance improvement 686-P
 Performance measurement 18-OR
 Performance 840-P
 Pericardial adipose tissue 73-OR, 1564-P
 Pericytes 1945-P, 2566-PO
 Perinatal factors 1220-P
 Perinatal nutrition 1935-P
 Perinatal outcomes 1283-P
 Periodontal disease 1460-P, 1510-P, 2514-PO
 Periodontal microbes 1571-P
 Periodontal 701-P
 Periodontitis 1326-P, 1460-P, 1917-P, 2536-PO,
 2646-PO
 Peripheral arterial disease 634-P
 Peripheral clocks 1912-P
 Peripheral neuropathy 113-OR, 118-OR, 568-P,
 576-P, 577-P, 1419-P, 1456-P
 Peripheral vascular disease 414-P
 Perivascular adipose tissue 486-P, 1837-P
 Perivascular fat cells 432-P
 Permanent neonatal diabetes 2426-PO
 Peroxiredoxin6 1687-P
 Peroxisome proliferator-activated receptor- γ coact
 519-P
 Peroxynitrite 2104-P
 Persistence 982-P, 1546-P
 Person centered outcomes 794-P
 Personality 2308-PO
 Personalized medicine 1165-P

- PET imaging 1037-P
 Pet ownership 1250-P
 PET scan 743-P
 PET 325-OR
 PET-MRI 2031-P
 PEX168 2385-PO
 PGC-1a 88-OR, 630-P, 1658-P, 2014-P, 2075-P
 Ph 2173-P
 Pharmacist training 703-P
 Pharmacist 12-OR, 705-P
 Pharmacodynamics 131-OR, 896-P, 896-P, 910-P, 932-P, 1017-P, 1021-P
 Pharmacoeconomics 12-OR
 Pharmacogenetics 1114-P, 1597-P, 1597-P, 1614-P, 2556-PO, 2561-PO
 Pharmacogenomics 153-OR
 Pharmacokinetics 129-OR, 131-OR, 892-P, 899-P, 910-P, 1021-P, 1116-P
 Pharmacologic inhibitors 1713-P
 Pharmacological therapeutic 1142-P
 Pharmacotherapy 1046-P
 Phase 1 clinical trial 977-P
 Phenotype race disease onset ethnicity 1361-P
 Phenotype 1359-P
 Phenotypic heterogeneity 1938-P
 Phosphoenolpyruvate 2177-P
 Phosphofetuin-A 367-OR, 2064-P
 Phospholipid remodelling 2194-P
 Phospholipid 1851-P
 Phosphorylation 228-OR, 2196-P
 Photoreceptors 598-P
 Photovoice 826-P
 Phthalates 1500-P
 Physical activity counseling 2297-PO
 Physical activity 157-OR, 222-OR, 262-OR, 732-P, 733-P, 788-P, 950-P, 2316-PO, 2317-PO
 Physical function 1321-P
 Physical performance 742-P
 Physician acceptability 1155-P
 Physician practice patterns 1180-P
 Physicians 1538-P
 PI3K/Akt/enos signaling pathway 496-P
 Pigment epithelium-derived factor 535-P
 Pima Indian 1534-P, 1585-P
 Pin1 1847-P
 Pioglitazone therapy 2281-PO
 Pioglitazone 111-OR, 960-P, 1109-P, 1110-P, 1111-P, 1114-P, 1127-P, 1136-P, 1148-P, 1835-P, 2134-P
 PK/PD 989-P
 PKB isoforms 41-OR
 PKC 240-OR, 1768-P, 2156-P
 Pkcdelta dependent phosphorylation of 14-3-3zeta 109-OR
 Placenta 213-OR, 214-OR, 717-P, 1266-P, 1266-P, 1271-P
 Plantar pressure measurements 1419-P
 Plantar pressure 654-P, 660-P
 Plantar temperature 654-P
 Plant-based diet 2278-PO
 Plasma amino acids 1466-P
 Plasma fatty acids 1352-P, 1464-P
 Plasma fibrinogen 2638-PO
 Plasma volume 263-OR
 Platelet aggregation 2240-PO
 Platelet indices 609-P
 Pluripotent stem cells 2126-P
 Pneumococcal disease 2448-PO
 Pneumococcal vaccination 2535-PO
 PNPLA3 1200-P, 1798-P
 Podiatry 2452-PO, 2509-PO
 Point of care 864-P, 2280-PO
 Polycarophil 755-P
 Polycystic ovarian syndrome 0969-P, 1549-P
 Polymorphism 1614-P
 Polyneuropathy 574-P
 Polynomial method 873-P
 Polyunsaturated fat acids; salmon oil 1754-P
 Polyunsaturated fatty acid 2024-P, 2288-PO, 2642-PO
 POMC 240-OR
 Population level data 383-OR
 Population PK modelling 981-P
 Population registries 1502-P
 Population-based health promotion 1545-P
 Porcine islet 1662-P, 2572-PO
 Portion 740-P
 Post diagnosis 1254-P
 Post prandial glucose 129-OR, 2422-PO
 Postnatal growth 1451-P
 Post-natal 1290-P
 Postoperative glycemic control 911-P
 Postpartum diabetes mellitus 2483-PO
 Postpartum education 709-P
 Postpartum hba1c levels 1313-P
 Postpartum participation 2343-PO
 Postpartum screening 1312-P
 Postpartum weight retention 1313-P
 Postpartum 1315-P
 Post-prandial glucagon 971-P
 Postprandial hyperglycemia 952-P, 2400-PO
 Postprandial hyperlipidemia 210-OR
 Postprandial period 2289-PO
 Post-prandial plasma glucose 991-P
 Potassium channel 406-P
 Potassium trap 1139-P
 PPAR gamma 244-OR
 PPAR 1115-P, 1118-P
 PPARD 1844-P
 Pparg activation 1679-P
 PPARG 273-OR, 1663-P, 1663-P
 Ppargamma 509-P
 Pparδ 2160-P
 Prandial glycemic control 987-P
 Prandial insulin 130-OR
 Prandial 2309-PO
 Preadipocyte 1716-P
 Precision 2349-PO
 Preclinical 966-P, 988-P, 990-P, 2411-PO
 Preconception care 324-OR, 2481-PO
 Preconception counseling 769-P, 775-P
 Prediabetes screening 21-OR
 Prediabetes 20-OR, 72-OR, 113-OR, 190-OR, 296-OR, 466-P, 720-P, 734-P, 848-P, 1205-P, 1207-P, 1362-P, 1377-P, 1382-P, 1389-P, 1398-P, 1400-P, 1405-P, 1627-P, 1748-P, 1753-P, 1755-P, 1834-P, 2140-P, 2170-P, 2230-PO, 2234-PO, 2325-PO, 2328-PO, 2461-PO, 2529-PO, 2536-PO
 Prediction equation 1570-P
 Prediction graph 873-P
 Prediction 26-OR, 1327-P, 2030-P, 2533-PO
 Predictive modeling 1424-P
 Predictive value 1378-P
 Predictors 220-OR, 998-P, 2483-PO
 Preeclampsia 1269-P, 1476-P
 Pre-existing diabetes 1269-P
 Pre-existing hypertension 1269-P
 Pregestational diabetes 1285-P, 1469-P, 1470-P, 1471-P, 2474-PO, 2481-PO
 Pregnancy complications 1486-P
 Pregnancy outcomes 1277-P, 1286-P
 Pregnancy 202-OR, 211-OR, 930-P, 1264-P, 1264-P, 1275-P, 1279-P, 1282-P, 1289-P, 1293-P, 1294-P, 1296-P, 1300-P, 1301-P, 1302-P, 1306-P, 1309-P, 1310-P, 1311-P, 1316-P, 1335-P, 1394-P, 1461-P, 1999-P, 2118-P, 2475-PO
 Prehypertension 1725-P
 Premenopausal 1569-P
 Pre-mixed human insulins 2327-PO
 Pre-pregnancy body mass index 1313-P
 Prepregnancy diabetes 324-OR
 Pre-pregnancy risk factors 1288-P
 Pre-pregnancy weight 1484-P
 Prescription trends 2402-PO
 Prescription 1173-P
 Prevalence of comorbidities 2513-PO
 Prevalence of diabetes mellitus 1416-P, 1495-P
 Prevalence of diabetes HCM city 1366-P
 Prevalence 579-P, 604-P, 1303-P, 1370-P, 1496-P, 1501-P, 1551-P, 2526-PO, 2531-PO, 2532-PO, 2635-PO
 Prevent 664-P
 Preventable hospitalization 1174-P
 Preventing hypoglycemia and hyperglycemia 693-P
 Prevention 20-OR, 25-OR, 640-P, 640-P, 642-P, 698-P, 807-P, 1221-P, 1479-P, 1545-P, 1646-P, 2325-PO
 Preventive services 1556-P
 PRF 2291-PO
 Primary care 318-OR, 706-P, 778-P, 780-P, 1150-P, 1151-P, 1161-P, 1161-P, 1527-P, 2297-PO, 2431-PO, 2489-PO
 Primates 1964-P
 Principal component analysis 1314-P
 Private insurance 1175-P
 Probiotics 1278-P
 Problem solving 13-OR, 1226-P
 Probnp 464-P
 Progenitor cells 508-P, 734-P, 2283-PO
 Progenitor 2124-P, 2133-P
 Progeroid appearance 2464-PO
 Progression to diabetes 362-OR
 Proinflammation 1671-P
 Proinsulin dimerization 2169-P
 Proinsulin misfolding 2169-P
 Proinsulin processing 2399-PO
 Prolactin 1275-P, 2189-P, 2190-P
 Proliferation 2135-P
 Prongf 349-OR
 Proof of concept 332-OR
 Pro-opiomelanocortin (POMC) neurons 239-OR
 Proopiomelanocortin 1918-P
 Propolis 656-P
 Prospective study 423-P, 641-P, 1518-P, 2232-PO
 Prostaglandin reductase-2 183-OR
 Prostaglandin transporter 644-P
 Prostaglandin 183-OR
 Prostate cancer 1759-P
 Proteasome 1779-P, 1869-P
 Protection 2175-P
 Protective 2098-P
 Protein breakdown 1717-P
 Protein kinase C 1621-P, 1710-P, 2139-P
 Protein kinase D1 2153-P
 Protein microarray 1245-P, 1642-P
 Protein phosphatase 2A 1722-P
 Protein sparing modified fast 2321-PO
 Protein uptake 302-OR
 Protein 55-OR, 946-P
 Proteinuria 1511-P
 Proteomics 540-P, 1672-P, 1960-P, 2052-P
 Protocol 2211-PO
 Proton pump inhibitors 2425-PO

- Provider trust 758-P
 Proximal tubular cell 530-P
 Psoriasis 2388-PO
 Psychological insulin resistance 779-P
 Psychology 796-P
 Psychometrics 768-P, 1244-P
 Psychomotor speed 1457-P
 Psychosocial interventions 781-P
 Psychosocial issues 806-P
 Psychosocial precarity 1274-P
 Psychosocial screening 824-P
 Psychosocial 772-P, 774-P
 Psychotic illness 2315-PO
 PTEN 1622-P, 1730-P
 PTP1B inhibitor 1068-P
 Public health surveillance 1425-P
 PUFA 2288-PO
 Pulmonary alveolar basement membrane 53-OR
 Pulmonary 1401-P
 Pulse pressure amplification ratio 2432-PO
 Pulse pressure 2505-PO
 Pulse wave velocity 1261-P
 Pump 912-P
 Purinergic system 180-OR
 Pyruvate dehydrogenase 500-P, 1729-P
 Pyruvate kinase 2177-P
 Pyruvate 1835-P
 QOL 358-OR
 Qpcr 1880-P
 QT intervals 2274-PO
 Qtc-time 590-P
 Qualitative study 819-P, 1242-P
 Quality improvement 1238-P, 2451-PO
 Quality indicators 1172-P, 1449-P
 Quality measures 1047-P
 Quality of care 1172-P, 2459-PO
 Quality of life 259-OR, 675-P, 746-P, 759-P, 795-P, 797-P, 809-P, 810-P, 817-P, 819-P, 1158-P, 1247-P, 2271-PO, 2468-PO, 2528-PO
 Quantile regression 1167-P
 Quantitative sensory testing 2269-PO
 Quercitrin 1131-P
 Questionnaire 2295-PO
 Rabbit 422-P
 RAGE 0257-OR, 447-P, 517-P, 565-P, 1003-P, 1004-P, 1095-P, 1368-P, 1698-P
 Ramadan 1296-P
 Raman spectroscopy 1263-P
 Random plasma glucose 1365-P
 Randomized community trial 2059-P
 Randomized controlled trial 238-OR, 256-OR, 1024-P, 1593-P, 2415-PO
 Ranolazina inal inhibitor 1088-P
 Rapamycin 2120-P, 2181-P
 Rapid response 1007-P
 Raptor 2188-P
 Rare coding variants 1609-P
 Rare variant 1615-P
 Rate of change 836-P
 Rats 1703-P, 1990-P
 RAW264.7 macrophages 2242-PO
 RBP4 2238-PO
 RDCVF2 598-P
 Reactive oxygen species 1053-P, 1630-P, 1641-P, 2191-P
 Readmission 1508-P
 RE-AIM 778-P
 Real life data 976-P
 Real-time data collection 762-P
 Reasons for discontinuation 982-P
 Recall system 1312-P
 Receptor for advanced glycation endproducts (RAGE) 506-P
 Recombinase-mediated cassette exchange 2674-PO
 Red kidney bean 754-P
 Redox modulation 1980-P
 Redox 1624-P
 Reduced beta2-glycoprotein I 607-P
 Reducing cardio-metabolic risk in young subjects 1525-P
 Reducing hypoglycemia 2223-PO
 Reg 2101-P
 Reg3 α 2567-PO
 Regeneration 2140-P
 Regenerative medicine 2141-P
 Registry 18-OR
 Regulators of G-protein signaling 2195-P
 Regulatory T cells 174-OR, 176-OR, 1637-P
 Relatives of patients with T1DM 832-P
 Reliability 431-P
 RELM beta 1808-P
 Renal disease 1341-P
 Renal effects 1899-P
 Renal expression 516-P
 Renal failure 2413-PO
 Renal function 54-OR, 1544-P
 Renal impairment 980-P, 992-P, 1010-P, 1025-P, 1026-P, 1035-P, 1035-P
 Renal outcome 544-P
 Renal reabsorption 1037-P
 Renal replacement therapy 1453-P
 Renal safety 1036-P
 Renal transplantation 1628-P
 Renal 965-P
 Reparative angiogenesis 242-OR
 Replication 2190-P
 Reproducibility 2346-PO
 Reproductive health 775-P
 Reprogramming 2130-P, 2138-P
 Rescue pen 390-P
 Rescue 2387-PO
 Resident 1193-P
 Resilience 808-P, 1244-P
 Resistance exercise 722-P, 862-P
 Resistance training 720-P
 Resistant hypertension 621-P
 Resistin 1337-P, 1610-P, 1611-P
 Resolvin D1 1968-P
 Respiratory infection 2535-PO
 Response predictors 996-P
 Restart 898-P
 Restenosis 315-OR
 Resting heart rate 2498-PO
 Resting state fmri 251-OR
 Resuspension 932-P
 Resveratrol 144-OR, 1988-P, 2162-P
 Retinal angiogenesis 607-P
 Retinal blood flow 608-P
 Retinal characteristics 429-P
 Retinal microvasculature 1394-P
 Retinal vessels 592-P, 1335-P
 Retinopathy 340-OR, 350-OR, 351-OR, 354-OR, 538-P, 600-P, 1452-P, 1561-P, 1636-P
 Retrospective data review 1227-P
 Return-on-investment 12-OR
 Revascularization 415-P
 Reversal 554-P
 Rho kinase 349-OR
 Rhodopsin 606-P
 Rho-kinase 525-P
 RHR 2498-PO
 Rictor 289-OR
 Rimonabant 1674-P
 Risk appraisal 777-P
 Risk assessment 1595-P
 Risk factors disparities 1361-P
 Risk factors 78-OR, 1376-P, 2526-PO
 Risk markers 1338-P
 Risk model 1400-P
 Risk prediction models 1356-P
 Risk prediction 1348-P, 1393-P
 Risk score 679-P
 Risk stratification 1277-P
 Risk 805-P, 1427-P, 2435-PO, 2440-PO
 Risk-taking behavior 769-P
 RNA sequencing 1861-P
 ROCK1 1783-P
 Roflumilast 1686-P
 ROS 1821-P
 Rosemary extract 616-P
 Rosiglitazone 1914-P
 Rosmarinus officinalis 1657-P
 Rotenone 1781-P
 Round tree meetings 690-P
 Roux-en-Y gastric bypass surgery 2051-P
 Rural health 1439-P
 RXR 1084-P
 RYGB 1880-P
 Safety net population 321-OR
 Safety 269-OR, 1071-P, 1081-P
 Salicylate 1848-P
 Salivary inflammatory burden 1577-P
 Salsalate 121-OR
 Salt restriction 699-P
 Salt sensitivity 1886-P
 Salt-inducible kinase 1795-P
 Sarcopenia 2065-P
 Satiety 1995-P
 Satisfaction 798-P, 2299-PO
 Saturated fatty acid 489-P, 497-P
 Saudi Arabia 2468-PO
 Saxagliptin 152-OR, 252-OR, 544-P, 1029-P, 1057-P, 2403-PO, 2416-PO
 Scaffold 2569-PO
 School 31-OR, 689-P
 Schwann cells 2272-PO, 2566-PO
 SCN 1824-P
 Screening 71-OR, 361-OR, 611-P, 1290-P, 1316-P, 1383-P, 1384-P, 2446-PO
 Seasonal variation 1464-P
 Secretion 2180-P
 Selective insulin resistance 1721-P
 Self management support 677-P
 Self-care behavior 694-P
 Self-care 821-P
 Self-efficacy 760-P, 779-P, 2334-PO
 Self-induction 2203-P
 Self-management education 10-OR
 Self-management 317-OR, 671-P, 707-P, 708-P, 815-P
 Self-monitoring 260-OR, 678-P, 800-P, 844-P, 851-P, 859-P, 2350-PO
 Self-reported hypoglycemia frequency 394-P
 Semaglutide 1010-P, 2383-PO
 Sensor accuracy 870-P
 Sepsis 403-P, 1133-P
 Sequencing 1581-P
 SERCA 488-P, 2172-P
 Seroconversion of GAD antibodies 1566-P
 Serotonin receptor 3 2165-P
 Serotonin transporters 96-OR
 Serotonin 142-OR, 2189-P
 Serum bilirubin 475-P

- Serum metabolome, obesity 2055-P
 Serum proteome 1976-P
 Serum testosterone 481-P
 Serum uric acid 441-P, 2638-PO
 Severe hypoglycemia 249-OR, 2213-PO, 2214-PO, 2225-PO
 Sex differences 212-OR, 558-P, 1723-P
 Sex hormone 451-P
 Sex hormone binding globulin 1509-P, 2003-P, 2003-P
 Sex-specific 1603-P
 Sexual dimorphism 2052-P
 Sexual dysfunction 2515-PO
 SGLT inhibitor 1045-P
 SGLT1 146-OR, 1948-P
 SGLT1/2 386-OR, 1049-P
 SGLT2 inhibitor 267-OR, 512-P, 513-P, 530-P, 850-P, 1032-P, 1033-P, 1035-P, 1036-P, 1037-P, 1050-P, 1054-P, 1063-P, 1085-P, 1086-P, 1101-P, 1102-P, 1103-P, 2218-PO, 2418-PO
 Sham feeding 1761-P
 Shared medical appointment 1185-P, 1255-P, 2458-PO
 SHBG 362-OR
 Shear friction 217-OR
 Short-chain fatty acids 100-OR
 SHP-1 502-P
 Side-effect 624-P
 Signal transduction 861-P, 1696-P, 2600-PO
 Signaling 201-OR
 Signaling bias 1732-P
 Simulation 20-OR, 2679-PO
 Single molecule imaging 370-OR
 Single nucleotide polymorphisms 1378-P
 Single port 857-P
 Sirt1 and AMPK 1108-P, 1797-P
 SIRT1 1271-P, 1706-P, 1897-P, 1955-P, 2244-PO
 Sirtuin 1 616-P
 Sitagliptin 1022-P, 1042-P, 1061-P, 1065-P, 1190-P, 1431-P, 2357-PO, 2399-PO, 2437-PO
 Site specific pegylation 1005-P
 Skeletal muscle arterioles 1842-P
 Skeletal muscle ceramide 1873-P
 Skeletal muscle fat 2037-P
 Skeletal muscle fiber types 715-P
 Skeletal muscle hypertrophy 2616-PO
 Skeletal muscle phosphoproteome 729-P
 Skeletal muscle secretome 1844-P
 Skeletal muscle 369-OR, 1088-P, 1709-P, 1837-P, 1839-P, 1846-P, 1860-P, 1863-P, 1867-P, 1869-P, 2258-PO
 Skin autofluorescence 410-P, 1273-P, 1350-P
 Skin biopsy 2273-PO
 Skin fluorescence 1432-P
 Skin intrinsic fluorescence 1249-P
 Skin thickness 2376-PO
 Skin 645-P, 1422-P, 1422-P
 SLC47A1 1596-P
 Sleep apnea syndrome 479-P
 Sleep duration 947-P
 Sleep quality 814-P, 2212-PO, 2336-PO
 Sleep structure 479-P
 Sleep 2071-P
 Sleepiness 2212-PO
 Sleeve gastrectomy 1704-P, 1705-P
 Sliding scale 1162-P
 Small fiber neuropathy 573-P, 580-P
 Small maf factors 2168-P
 Small molecule 155-OR, 156-OR, 2129-P
 Smartphone 881-P, 955-P
 SMBG 1253-P, 1497-P, 1504-P, 2390-PO
 Smoking 439-P, 1350-P, 1401-P, 2302-PO
 Smooth muscle cell 486-P
 Smrna 1921-P
 Snail 531-P
 SNAP23 632-P
 SNP 364-OR, 702-P, 1105-P, 1611-P, 2555-PO
 Social club meetings 2312-PO
 Social cognitive theory 780-P
 Social conditions 1542-P
 Social deprivation 1456-P
 Social factors 793-P
 Social support 801-P
 Sociocultural barriers 2471-PO
 Sociodemographic risk factors 1222-P
 Socio-economic status 1502-P
 Sodium glucose co-transporter 2 (SGLT2) 109-OR, 263-OR, 265-OR, 268-OR, 512-P, 532-P, 1034-P, 1051-P, 1078-P, 1092-P, 1093-P, 1094-P, 1095-P, 1096-P, 1107-P
 Soluble insulin receptor 471-P
 Soluble leptin receptor 2642-PO
 Somatostatin 303-OR
 Sortilin 208-OR
 South Asian 1287-P, 1389-P, 1407-P, 1472-P, 1509-P, 1525-P, 2538-PO
 Sp1 2589-PO
 Spain 2549-PO
 Sphingosine 1-phosphate 311-OR
 Spiritual well-being 797-P
 Srage 410-P, 527-P, 1602-P
 SREBP 94-OR
 Stable isotope 1703-P, 1883-P, 2461-PO
 STAM2 1613-P
 Standard of care 2296-PO
 STAT3 1946-P, 2206-P
 STAT5 2595-PO
 Statin for primary prevention 17-OR
 Statin treatment 438-P
 Statin 453-P, 491-P, 555-P, 612-P, 624-P, 1052-P, 1124-P, 1173-P, 1352-P, 2236-PO, 2285-PO, 2522-PO
 Statistical evaluation model 816-P
 Steatohepatitis 1800-P
 Steatosis 1770-P, 1980-P
 Stem cells 2633-PO, 2643-PO
 STEMI 1-OR
 Steroids 907-P
 Store-operated calcium entry 505-P
 Stress signaling 181-OR
 Stress 783-P, 823-P, 825-P, 1138-P
 Striatal dopamine transporters 2028-P
 Stroke 416-P, 420-P, 435-P, 2238-PO
 Structural variants 1583-P
 Structure 2676-PO
 Structured DSME program 2301-PO
 Structured self-monitoring of blood glucose 14-OR
 STZ 377-OR
 Subclinical atherosclerosis 1595-P
 Subclinical cardiovascular disease 336-OR
 Subcutaneous adipose layer thickness 2376-PO
 Subcutaneous fat 212-OR
 Subendocardial viability ratio 1144-P
 Substrate metabolism 710-P, 1867-P
 Substrate oxidation 1605-P
 Substrate switching 1822-P
 Subthreshold depression 828-P
 Subtotal gastrectomy 2054-P
 Sucralose 1785-P
 Sugar 1479-P, 1817-P
 Sugar-sweetened beverages 1557-P
 Suicide 805-P
 Sulfonylurea 335-OR, 399-P, 1089-P, 1328-P, 1426-P, 1521-P, 1522-P, 1597-P
 Sulforaphane 507-P
 Sulphonylurea 1069-P
 Summer camp 1248-P
 Sumoylation 488-P
 Superoxide dismutase 578-P
 Supplemental insulin 853-P
 Supramammillary 1927-P
 Supramolecular hydrogel 2292-PO
 SUR2 559-P
 Surveillance 171-OR
 Survey 772-P, 1528-P
 Survival 2148-P
 Sustained control 970-P
 Sweet taste receptor 1890-P, 2157-P
 Sweet-project 2541-PO
 Switch from glargine 904-P
 Sympathetic nervous stimulation 2043-P
 Sympathetic nerve activity 1065-P
 Symptom questionnaires 839-P
 Syndecan 2601-PO
 Syntaxin-4 2144-P
 System accuracy 844-P
 Systematic review 57-OR, 1523-P
 Systemic inflammation 751-P, 2525-PO
 Systolic blood pressure 974-P, 1423-P
 T cells 176-OR, 1639-P, 1641-P, 1645-P
 T lymphocytes 311-OR
 T regulatory 281-OR
 T1D pathogenesis 1647-P
 T2D human islets 304-OR
 Talking circles 11-OR
 Tamoxifen 1618-P
 Targets 782-P
 Task shifting, nurse care interventions 1188-P
 Taurine transporter 1561-P
 Taurine 2247-PO
 T-cell autoreactivity 1644-P
 Tcf19 2100-P
 TCF7L2 45-OR, 190-OR, 1605-P, 1617-P, 1791-P
 Team clinics 2458-PO
 Technology 852-P, 1226-P, 1226-P, 1302-P
 TEENS 32-OR, 259-OR, 1247-P
 Telemedicine 833-P, 955-P, 1243-P, 2310-PO, 2442-PO, 2454-PO
 Telemetry 1733-P
 Telomerase 428-P
 Telomere length 428-P
 Telomeres 2249-PO
 Ten-eleven translocation 2290-PO
 Teneeligliptin 2413-PO
 Testis 1952-P
 Testosterone 1509-P, 1876-P
 Teststeron 1951-P
 Text messaging 869-P
 TG storage 2012-P
 TGF-beta 1635-P
 TGF-β1 599-P
 Th1 Th17 anti-islet response 180-OR
 Th17 cells 2465-PO
 The health improvement network 601-P
 The metabolic syndrome 1014-P
 The transtheoretical model 1540-P
 Therapeutic agents 34-OR
 Therapeutic fasting 1483-P, 2328-PO
 Therapeutic re 2333-PO
 Therapeutic shoes 637-P
 Therapeutic targets 2295-PO, 2460-PO
 Therapy intensification 449-P

- Therapy 796-P
Thermosensitive matrix 953-P
Thiazolidinediones 1122-P
Thigh fat 1343-P
Thioredoxin-interacting protein 44-OR, 242-OR, 2235-PO
Thrombin generation assay 491-P
Thymoglobulin 173-OR
Thyroid hormone analogues 1799-P
Thyroid hormone 203-OR, 1911-P, 2033-P, 2116-P, 2170-P
Thyroid stimulating hormone 209-OR, 469-P
Thyroid 340-OR
Thyroid-related hormones 2597-PO
Time delay 845-P
Tissue repair 567-P
TLR4 1936-P
TM4 1992-P
TNF- α 1717-P
Tobacco 818-P
Toll-like receptor 4 485-P, 2560-PO
Total internal reflection fluorescence microscopy 2149-P
Total pancreatectomy 86-OR, 1877-P, 1877-P
TPH1 2189-P
Trace elements 1476-P
Tracer kinetics 1822-P
Tracer recycling 1790-P
Training 736-P
Traits 2308-PO
Trajectory 1223-P
Transbuccal linsulin 956-P
Transcript 1584-P
Transcription 2101-P
Transcriptional activity 1615-P
Transcriptional co-activator with pdz binding motif 1707-P
Transcriptional factor 2589-PO
Transcriptional regulation 1680-P
Transcriptional repression 2661-PO
Transcriptome 1653-P
Transcriptomics 2552-PO
Transdermal delivery 953-P
Transdifferentiation 2121-P, 2146-P, 2146-P
Transition to adult care 1169-P
Transition 806-P, 933-P, 1242-P, 2378-PO
Transitional model 1224-P
Transitional trial 954-P
Transitions of care 2443-PO
Translation 698-P, 807-P
Translational model 2602-PO
Translocon 2154-P
Transmembrane proteins 2184-P
Transmetatarsal amputation 646-P
Transplant 345-OR
Transplantation 574-P, 635-P, 1659-P, 1675-P
Treatment durability 1515-P
Treatment inertia 1168-P
Treatment initiation 2522-PO
Treatment intensification 1184-P
Treatment patterns 1008-P, 1168-P, 1527-P, 2521-PO
Treatment satisfaction 786-P, 802-P
Treatment 127-OR, 128-OR, 1303-P, 1544-P, 2306-PO
Trend 170-OR, 1374-P, 1420-P
Trends in care, medicare population 1436-P
T-RFLP 280-OR
Triacylglycerol 1784-P
TRIB3 1695-P
Tribble 3 409-P, 411-P
Triglyceride 2289-PO
Triglycerides 112-OR, 587-P, 631-P
Trimethylamine 1743-P
TRIP-Br2 1930-P
Triple therapy 267-OR, 963-P
Troponin 454-P, 1346-P
Tubulointerstitial injury 545-P
Turnover 192-OR
Twelve month 1254-P
Twin study 463-P, 1505-P, 1994-P, 2055-P, 2537-PO
Two-dimensional difference gel electrophoresis 1976-P
Txnip 35-OR, 103-OR, 2093-P, 2093-P, 2106-P, 2155-P, 2193-P, 2193-P, 2203-P
Type 1 diabetes complications 1442-P
Type 1 diabetes prediction 271-OR
Type 2 diabetes patients with erectile dysfunction 1130-P
Type 2 diabetes prediction 1369-P
Type 2 diabetes progression 1964-P
Type 2 Diabetic cohorts 2302-PO
Tyrosine phosphorylation 1691-P
U-500 insulin 133-OR, 2479-PO
Ubc13 366-OR
Ubiquitin 366-OR
Ucn3 303-OR
UCP-1 1972-P, 2014-P, 2075-P
UCP3 1865-P
Udenafil 1130-P
UGE 1049-P
Ultra fast acting insulin 129-OR, 130-OR, 910-P, 956-P
Ultra-long acting insulin 894-P, 895-P, 903-P
Umbelliferone 1727-P
Unawareness of hypoglycemia 2209-PO
Unawareness 385-OR
Uncontrolled blood glucose 908-P
Uncontrolled DM2 11-OR
Underserved 2310-PO
Underweight 2324-PO
Undiagnosed diabetes 1489-P, 2003-P, 2003-P
Undiagnosed 1386-P
Undisclosed neuropathy in Romania;2271-PO
Unemployed 408-P
Unfolded protein response 197-OR, 308-OR, 2006-P
Unmet needs 908-P, 918-P
Unsaturated fatty acids 2008-P
Uric acid 109-OR, 1409-P, 2236-PO
Urinary ACE2 543-P
Urine microalbumin 1249-P
Urologic complications 576-P
Use reagent test strips 691-P
U-shaped association 1511-P
Utility 2436-PO
Validation 2435-PO, 2440-PO
Vascular adhesion molecules 1141-P
Vascular calcification 500-P
Vascular complications 450-P, 452-P, 487-P, 866-P
Vascular disease 489-P, 1573-P
Vascular endothelial function 2400-PO
Vascular endothelial growth factor 607-P, 1072-P, 2131-P, 2685-PO
Vascular function 372-OR, 2013-P, 2013-P
Vascular insulin resistance 713-P, 1725-P
Vascular risk 468-P, 2431-PO
Vascular smooth muscle cells 315-OR, 455-P, 502-P, 1689-P
Vascularization 501-P, 2128-P
Vasodilating b blocker 621-P
Vaspin 446-P
Vegetable Intake 1478-P
VEGF 597-P, 1272-P, 2287-PO, 2625-PO
Venous blood glucose 2347-PO
Very low calorie diet 301-OR, 1923-P, 2082-P, 2321-PO
Very low-density lipoprotein 290-OR
Vestibular disorders 1437-P
Veterans 1420-P
V-Go 2373-PO
Videoconferencing 1243-P
Vildagliptin 1058-P, 1070-P, 1293-P, 1752-P, 2224-PO, 2225-PO, 2410-PO
Viral infection 1245-P
Virtual reality 725-P
Virtual system 322-OR
Virus 1656-P
Virus-induced diabetes 1630-P
Visceral adipose tissue 1351-P, 1387-P, 2575-PO
Visceral adiposity index 452-P, 2648-PO
Visceral adiposity 1518-P
Visceral fat 2048-P, 2084-P
Visfatin 2594-PO
Vision and ocular complications 591-P, 602-P
Visit frequency 1254-P
Vitamin B12 deficiency 1692-P, 2407-PO
Vitamin B12 1087-P
Vitamin C 1053-P
Vitamin D deficiency 1494-P, 2325-PO
Vitamin D receptor 2246-PO
Vitamin D 90-OR, 107-OR, 546-P, 552-P, 623-P, 745-P, 747-P, 1233-P, 1441-P, 1462-P, 1474-P, 1514-P, 1523-P, 2079-P, 2240-PO, 2330-PO, 2331-PO, 2652-PO
Vitamin E 1962-P
VLDL and lipid oxidation 714-P
VLDL 1856-P
VLDL-triglyceride kinetics 2011-P
VMH 146-OR
Volume depletion 1031-P
Voluntary exercise 712-P
Vulnerable populations 408-P
Waist circumference 2503-PO
Waist-to-height ratio 2634-PO
Walking 460-P
Water reabsorption 1944-P
Web-based survey 724-P, 2332-PO
Website interaction 2342-PO
Weight change 75-OR, 802-P, 1524-P
Weight gain 72-OR, 2089-P, 2324-PO, 2359-PO
Weight loss 99-OR, 126-OR, 261-OR, 339-OR, 776-P, 790-P, 967-P, 1046-P, 1153-P, 1213-P, 1480-P, 1948-P, 2009-P, 2038-P, 2039-P, 2044-P, 2064-P, 2323-PO, 2631-PO
Weight loss/weight regain 1593-P
Weight management 1217-P
Weight regain 2081-P
Western diet 1817-P
Whey 741-P
White adipose tissue 1669-P
White matter hyperintensities 333-OR
WHO 1411-P
Whole exome sequencing 1607-P, 2557-PO
Wnt signaling 45-OR, 1700-P, 1791-P, 2018-P
Women 1292-P, 1335-P
Women's health 1486-P
Worksite intervention 2645-PO
Wound dressings 2292-PO
Wound healing 313-OR, 417-P, 501-P, 644-P, 645-P, 649-P, 651-P, 662-P, 1142-P
Wrist circumference 2503-PO
Xanturenic acid 2683-PO
Xenin 1741-P
Xenotransplantation 1662-P, 2572-PO

Xmeta a novel insulin receptor activator
123-OR

Xmeta 1732-P

Young adults 806-P, 826-P, 827-P, 1224-P, 2312-PO,
2341-PO

Youth 258-OR, 788-P, 812-P, 0948-P, 1163-P, 1196-P,
1203-P, 1203-P, 1255-P, 1498-P, 2507-PO

Z-BMI 162-OR

Zebrafish 276-OR

Zeta potential 841-P

Zinc transport 2676-PO
ZS-9 553-P